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Abstract
Most of the human genome is noncoding but knowing how and when genetic variation in noncoding
regions of the genome can impact biology and disease susceptibility remains challenging. Here, we apply
an integrated genomics approach towards understanding and elucidating new patterns of functional
genetic variation in untranslated regions of protein-coding messenger RNAs.
G-quadruplex (G4) sequences are abundant in untranslated regions (UTRs) of human messenger RNAs,
but their functional importance remains unclear. In Part 1 of this dissertation, we integrate multiple
sources of genetic and genomic data to show that putative G-quadruplex forming sequences (pG4) in 5’
and 3’ UTRs are selectively constrained and enriched for cis-eQTLs and RNA-binding protein (RBP)
interactions. Using over 15,000 whole genome sequences, we find evidence of strong negative selection
acting on central guanines of UTR pG4s. At multiple GWAS-implicated SNPs within pG4 UTR sequences,
we find robust allelic imbalance in gene expression across diverse tissue contexts in GTEx, suggesting
that variants affecting G4 formation in UTRs may also contribute to phenotypic variation. Our results
establish UTR G4s as important cis-regulatory elements and point to a link between disruption of UTR
pG4 and disease.
In Part 2 of this dissertation, we examine patterns of selective pressure in non-canonical open reading
frames (ncORFs) mapped throughout the human genome. Ribosome-profiling has uncovered pervasive
translation in ncORFs, however the biological significance of this phenomenon remains unclear. Using
genetic variation from 71,702 human genomes, we assess patterns of selection in translated upstream
open reading frames (uORFs) in 5’UTRs. We show that uORF variants introducing new stop codons, or
strengthening existing stop codons, are under strong negative selection comparable to protein-coding
missense variants. Using these variants, we map and validate new gene-disease associations in two
independent biobanks containing exome sequencing from 10,900 and 32,268 individuals, respectively,
and elucidate their impact of protein expression in human cells. Our results suggest new mechanisms
relating uORF variation to reduced protein expression and demonstrate that translation at uORFs is
genetically constrained in 50% of human genes.
Together, these studies help emphasize the importance of noncoding RNA regulatory elements in
mediating post-transcriptional regulation of gene expression and illuminate new patterns of functional
variation in UTRs with human disease relevance.
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ABSTRACT
INSIGHTS INTO FUNCTIONAL NONCODING RNA ELEMENTS THROUGH THE ANALYSIS OF
HUMAN GENETIC VARIATION
David S.M. Lee
Yoseph Barash
Louis R. Ghanem
Most of the human genome is noncoding but knowing how and when genetic variation in
noncoding regions of the genome can impact biology and disease susceptibility remains
challenging. Here, we apply an integrated genomics approach towards understanding and
elucidating new patterns of functional genetic variation in untranslated regions of protein-coding
messenger RNAs.
G-quadruplex (G4) sequences are abundant in untranslated regions (UTRs) of human messenger
RNAs, but their functional importance remains unclear. In Part 1 of this dissertation, we integrate
multiple sources of genetic and genomic data to show that putative G-quadruplex forming
sequences (pG4) in 5’ and 3’ UTRs are selectively constrained and enriched for cis-eQTLs and
RNA-binding protein (RBP) interactions. Using over 15,000 whole genome sequences, we find
evidence of strong negative selection acting on central guanines of UTR pG4s. At multiple
GWAS-implicated SNPs within pG4 UTR sequences, we find robust allelic imbalance in gene
expression across diverse tissue contexts in GTEx, suggesting that variants affecting G4
formation in UTRs may also contribute to phenotypic variation. Our results establish UTR G4s as
important cis-regulatory elements and point to a link between disruption of UTR pG4 and disease.
In Part 2 of this dissertation, we examine patterns of selective pressure in non-canonical open
reading frames (ncORFs) mapped throughout the human genome. Ribosome-profiling has
uncovered pervasive translation in ncORFs, however the biological significance of this
phenomenon remains unclear. Using genetic variation from 71,702 human genomes, we assess
patterns of selection in translated upstream open reading frames (uORFs) in 5’UTRs. We show
that uORF variants introducing new stop codons, or strengthening existing stop codons, are
under strong negative selection comparable to protein-coding missense variants. Using these
variants, we map and validate new gene-disease associations in two independent biobanks
containing exome sequencing from 10,900 and 32,268 individuals, respectively, and elucidate
their impact of protein expression in human cells. Our results suggest new mechanisms relating
uORF variation to reduced protein expression and demonstrate that translation at uORFs is
genetically constrained in 50% of human genes.
Together, these studies help emphasize the importance of noncoding RNA regulatory elements in
mediating post-transcriptional regulation of gene expression and illuminate new patterns of
functional variation in UTRs with human disease relevance.
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CHAPTER 1: THE REGULATORY RENAISSANCE

1.1: How many genes?
In 1999 the New York Times published estimates from scientists at the Incyte Corporation that
the human genome contained approximately 140,000 genes. This represented a ~40% increase
over the consensus estimate by many researchers at the time, with most previous estimates
falling between 50,000-100,000. Many assumed that more complex organisms, like humans,
necessitated a greater number of genes to support their biological complexity. As early as 1951 it
had been observed that genome size appeared to increase with organismal complexity from
invertebrates to vertebrates [1]. However, when the first working draft human genome was
published in 2001, many were surprised to find evidence supporting the existence of only 3040,000 protein coding genes [2]. Three years later, this estimate was further reduced to 21,000 almost 20% less than in the zebrafish genome (~26,000) [3,4]. The paucity of protein coding
genes in the draft human genome challenged the view that more complex organisms encoded
more proteins in their genomes, and raised an important question: What was the source of
human biological complexity?
The discrepancy between perceived organismal complexity and the number of protein coding
genes came to be known as the “G-value Paradox”. One proposed resolution to this paradox
hypothesized that biological complexity more likely arose from a milieu of regulatory interactions
between a limited set of protein-coding genes rather simply encoding more genes in the genome.
These ideas were pioneered by Roy Britten and Eric Davidson in a 1969 essay published in
Science [5], writing that:
Nonetheless, it seems unlikely that the 30-fold increase from poriferan to mammal can be
attributed to a 30-fold increase in the number of producer [protein-coding] genes … Quite
possibly, the principal difference between a poriferan and a mammal could lie in the
1

degree of integrated cellular activity, and thus in a vastly increased complexity of
regulation rather than a vastly increased number of producer genes.

We now recognize that substantial biological complexity arises through multiple layers of
regulation - from the intracellular processes that govern gene expression and alternative splicing,
to tissue-level and whole-organism levels of regulation that contribute to physiology and
pathology. Many diseases result from otherwise protective physiologic processes - including
fibrosis, inflammation, and immune activation - that become co-opted and dysregulated to
produce pathology. Understanding the contribution of our genetics to how these processes
become dysregulated can not only help expand our appreciation of disease biology, but also
inform new targeted approaches towards therapeutic development.

1.2: Genetic variation and common disease
A crucial motivation for sequencing the human genome was to better understand the relationship
between genes and disease. Shortly after the first draft human sequence was completed, the
International HapMap was formed to create a database of common single nucleotide
polymorphisms (SNPs) across diverse human populations [6]. The formation of this database
facilitated a wave of genome wide association studies (GWAS) through which researchers sought
to associate common genetic variants with numerous human phenotypes [7]. A typical GWAS
required genotyping large cohorts of individuals at 300,000 - 5 million SNPs selected for their
ability to provide broad coverage across the human genome by being in linkage disequilibrium
with as many nearby genetic variants as possible [8]. Each genotyped SNP therefore represented
a block of commonly co-inherited genetic variants, all in linkage disequilibrium. Association tests
were then performed between genotyped SNPs and phenotypes of interest to determine whether
specific alleles at these variants were. Phenotypes of interest could include true disease cases
2

versus controls, or with continuous traits like height or QT interval. When statistically significant
associations were uncovered, discriminating between one or multiple true causal variants among
co-inherited blocks of SNPs required additional fine-mapping and functional studies. Since most
genetic variants uncovered through association studies resided in noncoding regions of the
genome, the relationship between these variants, the genes they impacted, and how they related
to the phenotypes being studied were rarely immediately obvious [8].
Even when GWAS lead variants fell within the boundaries of annotated genes, the possibility of
long-range interactions made simple approaches including connecting the biological impact of tag
GWAS SNPs to their nearest genes dubious. In a well-known example, a functional SNP
associated with lactose intolerance (rs4988235) was found to reside within an intron of the
minichromosome maintenance complex component 6 (MCM6) gene. Although it was known that
expression of the lactase (LCT) gene was crucial for maintaining lactose tolerance, rs4988235
was located 13.9 kilobases upstream of LCT [9]. Despite being in the intron of MCM6,
subsequent molecular studies showed that rs4988235 was indeed capable of modulating LCT
expression by disrupting a distal enhancer element that is active only in lactase-producing
enterocytes [10]. Thus, although GWAS were highly effective at uncovering sets of candidate
variants associated with common diseases, identifying the true subset of causal genetic variants,
and understanding how these variants connected specific genes to disease phenotypes remained
challenging, particularly for disease contexts where no clear connection could be made between
gene function and disease pathology.
Indeed, over 90% of disease-associated genetic variants identified through genome-wide
association studies occupy noncoding regions of the genome [8]. These variants are broadly
hypothesized to disrupt regulatory processes important for controlling normal biological functions,
however interpreting their potential biological impact has remained challenging. In protein-coding
DNA sequences, biological information is encoded in the form of codons that directly correspond
3

to amino acids. In contrast, noncoding regions of the genome can contain regulatory information
that is often encoded as DNA sequence motifs. Making informed hypotheses on the mechanistic
impact of genetic variation in noncoding DNA - in particular small insertions, deletions, or
substitutions - is challenging both because much of the noncoding genome may not be functional,
because many biological motifs are degenerate, and the specific mechanisms by which genetic
variation impacts the activity of functional noncoding motifs are often unclear [11]. Thus, the
promise of identifying specific biological mechanisms relating genetic variation to disease
remained difficult for the vast majority of GWAS-uncovered SNPs.

1.3: The challenge of interpreting noncoding variation
Nevertheless, prior to the age of GWAS, traditional molecular biology approaches characterized
numerous examples of noncoding genetic variants affecting DNA regulatory elements, including
transcription factor binding sites [12], distal-acting transcriptional enhancers or silencers [13], and
epigenetic regulatory marks that drive the pathogenesis disease [14]. Early studies of the 𝛽-globin
gene were the first to demonstrate that genetic variants disrupting noncoding regulatory DNA
could cause human disease [15]. It had been known previously that large deletions affecting the
𝛽-globin gene produced thalassemias in patients. Unexpectedly, two patients were found to also
manifest clinical and histological symptoms of classic 𝛽-thalassemia despite having a completely
intact 𝛽-globin gene [16]. Restriction mapping revealed large deletions in these patients
occupying noncoding DNase I hypersensitive sites far upstream of the 𝛽-globin gene. Further
molecular studies elucidated that deletion of these DNase I hypersensitive sites led to loss of 𝛽globin expression, confirming a role for noncoding DNA in regulating gene expression, and also
directly linking the disruption of noncoding regulatory DNA elements far upstream of encoded
proteins to disease phenotypes [17].

4

The recognition that noncoding genetic variants could affect gene expression, sometimes over
long ranges, provided one avenue for linking noncoding variants to their impact on genes, and
ultimately genes to disease. The ability to capture global profiles of gene expression from
biological samples through microarrays and high-throughput sequencing facilitated association
studies between catalogued common genetic variants and changes in gene expression. Common
variants found to be significantly associated with changes in gene expression, or expression
quantitative trait loci (eQTLs) could now be mapped and identified for all 20,000 protein coding
genes. The largest of these studies, the Genotype-Tissue Expression (GTEx) project,
accumulated genotype, and gene expression profiles for thousands of individuals across 49
tissues [18,19]. These eQTLs could provide a putative link between changes in noncoding DNA
and the activity of specific genes, and generate new hypotheses linking genes and disease.
Similar approaches were developed for other measurable quantitative molecular traits - including
levels of alternative splicing, degrees of chromatin accessibility, DNA methylation, protein
expression, and metabolites among others [20]. Although these approaches could associate
noncoding genetic variants with molecular phenotypes in cells, ascertaining precisely how these
variants could change biological mechanisms remained elusive.

1.4: Untranslated regions in messenger RNA
While there is growing appreciation for the impact of noncoding genetic variation in human
disease, most previous work has focused on understanding the impact of this variation on
regulatory elements in DNA; in contrast, genetic variants affecting RNA have received
comparatively less focus. As genetic information in the genome is first transcribed from DNA to
RNA, and then translated from RNA to protein, understanding how genetic variation impacts RNA
function is central to forming a more complete picture of how genetic variation can affect protein
expression.
5

The 5’ and 3’ untranslated regions (UTRs) are core components of all mature messenger RNAs
(mRNAs) that contain regulatory elements controlling diverse post-transcriptional processes.
Indeed, it has been observed in yeast that the majority of the variance in mRNA stability can be
explained by cis-regulatory elements in UTRs and coding sequences [21]. Although these
distinctions are not absolute, the 5’UTR is broadly thought to influence mRNA translation by
modifying ribosome loading and the efficiency of translation initiation through structural elements
such as hairpins [22], internal ribosome entry sites (IRES) [23], and sequences capable of
initiating translation which include cognate or near-cognate start codons [24], and long repetitive
trinucleotide repeats [25,26]. In contrast, regulatory elements in 3’UTRs - including secondary
structure forming motifs and microRNA binding sites -are more broadly thought to modify posttranscriptional mRNA stability, determine subcellular localization, and influence ribosomal
recycling through interactions with the 5’UTR [27]. Moreover, sequence motifs in both 5’ and 3’
UTRs can serve as substrates for RNA binding proteins that greatly expand the repertoire of
possible post-transcriptional RNA interactions impacting how and when mRNAs are translated or
degraded. Thus, although genetic variants in both 5’ and 3’ UTRs have the capacity to affect
protein expression through diverse mechanisms, dissecting which UTR variants can functionally
impact biology from those that are silent remains challenging.
Examples of genetic variants in UTRs causing disease have been identified by traditional linkage
mapping approaches with experimental validations. Well-known functional elements within UTRs
with disease relevance include 3’UTR polyadenylation signals [28], microRNA binding sites [29],
and upstream open reading frames (uORFs) in 5’UTRs which modify translation [30]. Yet, broadly
understanding how mutations in these elements can affect the biological processes which lead to
pathology is difficult even when the functional impact of a mutation on a regulatory element is
known. As an example, systematic mutagenesis of the canonical polyadenylation signal AAUAAA
has elucidated the functional effects of all possible mutations on the motif’s function using
synthetic 3’UTR constructs [31]. Yet, because 3’UTR regulatory elements are often repeated and
6

can act synergistically [32], the ultimate effect of mutations in one of several potential
polyadenylation signals within a 3’UTR cannot be known without performing targeted biochemical
studies. A consequence of the ambiguity inherent in interpreting noncoding genetic variation is
that most known pathogenic variants are in the coding genome, even though many exome
sequencing approaches can capture variation in UTRs. Because of this, expanding our capacity
to interpret genetic variation in both 5’ and 3’ UTRs can have an immediate and direct impact in
clinical applications and our understanding of disease biology.

1.5: Identifying variants of interest in the noncoding genome
The falling cost of sequencing has led to the creation of large databases of human genetic
variation, facilitating new approaches to identify functional noncoding genetic variation. Under the
principle that functional elements within the human genome tend to be less tolerant to genetic
variation, identifying regions of the genome that are depleted of variation can help unmask
functional regulatory elements in noncoding DNA. Many studies have analyzed allele frequencies
to infer the action of natural selection on putative and predicted noncoding regulatory elements
throughout the genome. Broadly, allele frequencies in an isolated population are shaped by three
forces: mutation, drift, and selection. Genetic variants are introduced into the population through
random mutation - a process that tends to introduce variation throughout the genome at a nearly
constant rate [33]. Under the neutral theory of molecular evolution, most mutations have neutral
or negligible effects on an organism's fitness and therefore will either be randomly removed from
the population, or rarely, will become fixed in a population due to genetic drift [34]. Even more
rarely, a mutation can be beneficial to an organism’s fitness, and selection may cause its allele
frequency to increase within a population in a process known as positive selection. A hard sweep
occurs when a beneficial mutation is introduced into a population by random mutation and rapidly
reaches fixation [35]. Alternatively, positive selection may manifest as a soft sweep - when
7

changes in the environment make a previously neutral variant present within the population
beneficial and its allele frequency increases [36].
In contrast, when a mutation has deleterious effects on an organism’s fitness, negative, or
purifying selection, tends to remove it from the population [33]. Thus allele frequencies for
deleterious variants tend to remain low within a population, and by extension deleterious classes
of mutations - such as protein truncating mutations, or mutations affecting essential splice sites will exhibit enrichment in rare allele frequencies compared to classes of genetic variation that are
selectively neutral [37]. This relationship between selection and allele frequencies can be used to
explore hypotheses and identify new classes of functional genetic variation in the human
genome.
Prior to the generation of large databases of human genetic variation, putative noncoding
regulatory elements were identified by comparing genome alignments from multiple species.
Many early approaches relied on detecting non-neutral substitution rates over particular genome
segments compared to expectation based on genetic drift [38]. Although effective at identifying
long stretches of conserved sequences in the human genome, the power of these methods to
detect non-neutral substitution rates at the individual nucleotides was limited by comparison,
particularly at moderately conserved bases [38]. By comparing strongly conserved sequences
across 29 different mammals, Lindblad-Toh and colleagues reported a map of human constrained
elements which also appeared to be depleted of single-nucleotide polymorphisms in human data
[39]. Thus, mutations affecting highly conserved noncoding DNA also appeared to be strongly
depleted of variation in human populations [39]. The increasing availability of sequenced human
genomes made it possible to implement approaches for inferring selection on specific genetic
variants or groups of nucleotide positions in the human genome based on their allele frequency
spectrum. Because functional regulatory elements in noncoding DNA are likely under a greater
degree of selective constraint compared to neutrally evolving DNA segments, the site frequency
8

spectrum of variants with deleterious impacts on these functional elements are also expected to
be enriched for rare allele frequencies.
Studies inferring the importance of microRNA regulatory sites in humans were among the first to
apply the relationship between selection and allele frequencies in human genomes. Using allele
frequencies from the 1000 Genomes Project Chen et al. found that SNPs affecting
computationally predicted conserved microRNA binding sites throughout the genome were
enriched for rare allele frequencies compared to other conserved sequence motifs in 3’UTR
sequences, suggesting that these sites were under a greater degree of negative selection [40].
By analyzing SNP density and the site frequency spectrum of genetic variants affecting ~22,000
predicted microRNA binding sites conserved across 5 mammals, Chen and colleagues
uncovered a significant depletion of genetic variation affecting these elements, suggesting that
they were also more likely to be functionally important in 3’UTRs. Similar approaches have been
used to examine patterns of selection on RNA-protein binding sites in RNAs [41], long-noncoding
RNAs [42], and sites of m6A methylation in human mRNAs [43].
As the volume of sequencing data has increased, subsequent refinements have been made to
this approach, most notably with the publication of the ExAC database in 2014 [37]. Here, Lek et
al. developed a method to quantify the enrichment of rare allele frequencies for a given class of
genetic variation using synonymous coding variants as a baseline for neutral selection, while
adjusting for different rates of mutation based on local sequence context. This metric - termed the
Mutability Adjusted Proportion of Singletons (MAPS) - has been applied to elucidate new classes
of putatively functional genetic variation by identifying groups of variants under stronger negative
selection compared to synonymous variants in coding regions of the genome. Indeed this
approach has been applied to identifying deleterious classes of coding mutations [44], new
putative splice-site disrupting mutations [45], and genetic variants creating new upstream open
reading frames in mRNA 5’UTRs [46]. A key advantage of this approach is that biologically9

informed hypotheses made about the potential functionality of a given class of genetic variants
can be evaluated by analyzing their allele frequency spectrum in large population-scale
databases.
Here, we have applied metrics of negative selection across human cohorts to study noncoding
regulatory elements in RNAs. To illuminate possible mechanistic relationships between genetic
variation and gene regulation, we take a hypothesis-driven approach to assess the significance of
specific classes of variation affecting both predicted and experimentally mapped RNA regulatory
elements. We have additionally used a combination of public genotype and phenotype databases
to explore the relevance of these variants to human disease. We have selected putative
regulatory elements based on the availability of experimental data to support their existence
across a large fraction of human mRNAs, and previously published literature supporting their
potential functionality. The focus of this thesis is twofold: In Chapter 2, we investigate whether
there is evidence for a functional role of G-quadruplex forming sequences in mRNA UTRs. In
Chapter 3, we employ the same investigation framework to non-canonical open reading frames
(ncORFs). Using public repositories of ribosome profiling to identify ncORFs, we elucidate
selective pressures acting within these translated noncoding sequences and identify new patterns
of functional variation in upstream open reading frames. For a subset of the variants we identified
as functional and associated with disease, we performed luciferase assays to validate their effect
on the translation of the downstream gene. Importantly, beyond the functional variants identified
in this work, these studies represent a new approach to study and assess the impact of genetic
variation on cis-regulatory elements in mRNA UTRs.
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CHAPTER 2: INTEGRATIVE ANALYSIS REVEALS RNA G-QUADRUPLEXES IN UTRS
ARE SELECTIVELY CONSTRAINED AND ENRICHED FOR FUNCTIONAL
ASSOCIATIONS *

2.1: Secondary structures as RNA regulatory elements
Unlike DNA, the single-stranded nature RNAs significantly expands the possibility for intrastrand
base-pairing. RNA secondary structures have long been implicated in regulating gene expression
through diverse post-transcriptional mechanisms. Strong secondary structures in 5’UTRs are
known to repress translation of downstream coding sequences by blocking the formation of
ribosome translation initiation complexes [22,47]. Specific 5’UTR secondary structures have also
been observed to facilitate increased translation of downstream protein coding sequences
through serving as internal ribosome entry sites (IRES) [23], or possibly through blocking
translation initiation at inhibitory upstream open reading frames (uORFs) [22]. In contrast, 3’UTR
secondary structures have been found to mask microRNA binding sites [47,48], facilitate
interactions with RNA binding proteins [49,50], and regulate mRNA stability [51], or subcellular
localization [52–54].
Several experimental approaches have been developed to map secondary structures
transcriptome-wide [55–57]. These studies have generally uncovered an enrichment of secondary
structures in both 5’ and 3’ UTRs compared to protein coding sequences where strong structure
formation could disrupt translation elongation by ribosomes [58]. RNA secondary structures can
also facilitate interactions with RNA binding proteins - either through helicases that unwind and
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resolve secondary structure elements in the 5’UTR to facilitate translation initiation, or through
binding proteins which can mediate RNA subcellular localization [59].

2.2: G-quadruplexes are non-canonical secondary structures formed by nucleic acids
Guanine rich nucleic acid sequences can form non-canonical secondary structures known as Gquadruplexes (G4s) in both DNA and RNA [60]. In contrast to DNA G4s, RNA G4s are thought to
form more readily in vitro due to their increased thermodynamic stability and reduced steric
hindrance [61,62]. G4 secondary structures are formed through non-canonical base pairing of
guanine side chains in G-rich sequences. The canonical G-quadruplex forming sequence
consists of four trinucleotide G-runs separated by 1-7 nucleotides (Fig. 2.1).

Figure 2.1: Canonical G-quadruplex motif. Schematic depicting a folded RNA parallel Gquadruplex with the accompanying canonical G4 forming sequence.

12

Transcriptome-wide G4 mapping studies have uncovered evidence for widespread G4 formation
in both 5’ and 3’UTR sequences [63,64]. In one approach, Kwok and colleagues developed a
method to map transcriptome-wide G4 structures (rG4) by measuring reverse transcriptase
stalling [63]. The method relies on isolating cellular mRNAs in vitro, while creating ionic conditions
that are favorable to RNA G4 formation. These RNAs are then treated with reverse transcriptase
(RT) to produce cDNA fragments which are isolated and subsequently sequenced. Because G4s
will induce RT-stoppage due to steric blockage, evidence of significant RT stopping can be used
to map secondary structures and identify G4 forming sequences within mRNAs transcriptomewide [63]. Results from these experiments uncovered specific enrichment of G4 structures in 5’
and 3’UTRs, and evidence that the capacity for G4 structure formation in mRNAs extends beyond
the canonical G4 motif to include structures with extended loops, bulges in G-runs, and two
quartets [63].
Although G4 formation has been studied extensively in vitro, whether G4s in mRNAs exist in vivo
has been an active area of debate. The single-stranded nature of RNAs is thought to favor G4
formation due to reduced steric hindrance, however some in cellulo structural probing
experiments using RT stopping have suggested that G4s typically exist unfolded at steady-state
in most eukaryotic cells [65]. Guo et al. modified the RT-stopping approach to map RNA
sequences capable of forming G-quadruplexes in vivo to probe for G4 formation in cellulo.
Strikingly, they observed that while most predicted RNA G4-forming (pG4) sequences were
unfolded at the steady-state, these same RNAs could form secondary structures when expressed
in prokaryotes, suggesting that eukaryotic cells harbored factors capable of unwinding these RNA
secondary structures [65].
While specific RNA G4s have been associated with diverse biological functions, including
mediating translational control [66,67], alternative splicing [68], subcellular localization [69], and
RNA stability [70,71], the transcriptome-wide functional importance of UTR G4s has largely been
13

extrapolated from a limited number of experimental studies. To address this question, we
combine several large-scale genomic and genetic data resources to assess evidence for
evolutionary constraint on UTR pG4 sequences in humans, and enrichment for functional
associations, including cis-eQTLs and protein binding sites. We show that UTR pG4 sequences
are subjected to heightened selective pressures, have enrichment for cis-eQTL variants as
identified by GTEx, and enrichment of RNA-protein binding interactions mapped by ENCODE.
Taken together, our results support the biological significance of UTR pG4 sequences and
highlight the importance of considering secondary structures in determining biological function in
noncoding regions of the genome.

2.3: pG4 exhibit heightened selective pressure within UTRs
Putative G-quadruplex (pG4) forming sequences are enriched within untranslated regions of
human messenger RNAs [63]. If these sequences are functional, they should exhibit patterns of
genetic variation consistent with heightened evolutionary constraint. To test this hypothesis, we
evaluated the distribution and frequency of single nucleotide variants occurring within UTR pG4
sequences using whole-genome sequencing data from over 15,000 individuals from the public
gnomAD release (version 2.2.1) [44]. We mapped pG4 sequences transcriptome-wide within
annotated UTRs using the canonical G4 motif - GGG-{N-1:7}(3)-GGG (Fig. 2,1). Consistent with
previous UTR G4 mapping efforts [72], we identified 2967 unique protein-coding genes encoding
for at least one transcript isoform containing a pG4 sequence within the 5’UTR, and 2835 proteincoding genes encoding a pG4 sequence within the 3’UTR. To further increase the specificity of
pG4 sequences, we additionally defined a subset of experimentally supported rG4 sequences
(466 in the 5’UTR, 1743 in the 3’UTR), consisting of canonical pG4 sequences with evidence of
secondary structure formation as determined by biochemical structure mapping approaches [63].
Under the expectation that deleterious variation is continuously removed from the population, we
14

expect allele frequencies for variants affecting UTR pG4 sequences to be skewed towards more
rare variation compared to non-pG4 UTR variants, reflecting their greater functional importance
[40,73,74]. Because allele frequencies throughout the genome are affected both by local
sequence context, which influences the mutability of a base at a given position, and nearby
constrained functional elements that are under linked selection, we compared only single
nucleotide variants affecting pG4 G-tracts to non-pG4 G-tracts (3 or more Gs) within UTRs
belonging to a subset of transcripts whose estimated levels of overall constraint matched our
UTR pG4-containing transcripts. This set of comparator transcripts was selected using the upper
90% bound of the observed vs. expected (LOEUF) metric, as published by gnomAD [44]. This
analysis revealed a significant depletion of variants in pG4 and rG4-seq G4s (Fig 2.2). For rG4
sequences, we found mean allele frequencies were approximately one-third of that compared to
non-pG4 G-tracts in constraint-matched transcripts in the 5’UTR, and 30% lower for the 3’UTR.
For pG4 sequences without direct experimental support, G-tract variant frequency differences
were similarly reduced (P<<2.2x10-16 for 5’UTR and 3’UTR; Fisher’s Exact Test). Taken together,
this reduction in mean allele frequencies for variants in 5’ and 3’UTR pG4 sequences relative to
those not affecting pG4 sequences is consistent with the effects of negative selection.
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Figure 2.2: Allele frequencies for G-run disrupting variants in gnomAD. Reduction in variant
frequencies affecting guanine G-tracts within UTR pG4 forming sequences compared to matched
non-pG4 G-tracts by transcript-level constraint. rG4-G-tracts are those within UTR pG4 that have
evidence of secondary structure formation by rG4-seq. Asterisks denote P-value <<2.2x10 by
Fisher’s exact test.
-16

To provide a complementary measure of sequence constraint, we assessed the number of
polymorphic sites within UTR pG4 sequences compared to non-pG4 sequences. We applied a
background model of neutral evolution to produce a distribution for the expected number of
polymorphic sites in a given region of the genome under the assumption of neutral selection. This
model has been shown to explain a median of 81% of the variability in nucleotide substitution
probabilities for noncoding regions of the genome based on the local heptamer context of a given
position [75]. Using this model, we partitioned UTR pG4 sequences into G-tracts and intervening
gap sequences, and compared the ratio of observed versus expected polymorphic sites in the
European sub-population of the 1000 Genomes Project. To additionally control for the possible
confounding effects of linked selection driven by nearby constrained coding elements, or
differences in sequencing depth across the 1000 Genomes Project, we produced an empirical
distribution for observed vs. expected substitutions in constraint-matched 5’ and 3’UTR
sequences. Consistent with the observed reduction in variant frequencies across UTR pG4s, we
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find a significant reduction in the number of observed versus expected polymorphic sites within
UTR pG4 sequences compared to non-pG4 forming regions of the UTR. Relative substitution
rates in 5’ and 3’ UTR G-tracts are reduced approximately 30-40% compared to non-pG4 regions
of constraint-matched UTRs (permuted P<10-4, for 5’ and 3’UTR pG4 and rG4) - Fig. 2.3. In
contrast, gap sequences that are not predicted to be important for secondary structure formation
in either 5’ or 3’ UTR pG4 contexts are not significantly different from the background UTR
estimates, consistent with a pattern of selective pressure in 3’UTR pG4 sequences that primarily
act to maintain the capacity for secondary structure formation across UTR pG4 sequences.

Figure 2.3: pG4-forming G-tracts are depleted of polymorphic sites compared to
intervening sequences. Reduction in the number of observed polymorphic sites compared to
expectation in 5’ and 3’ UTR pG4 forming G-tracts using a nucleotide substitution model based
on local sequence context (permuted P < 1x10 in all G-tracts compared to matched non-pG4
UTR sequences). Error bars represent bootstrapped 90% confidence intervals for the ratio of
observed vs. expected substitutions within each pG4 region. Red line and shaded regions
represent the observed vs. expected number of substitutions in non-pG4 UTR sequences
-4
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matched by transcript-level constraint and 90% confidence intervals, respectively. Gray-dashed
line represents an expected vs. observed ratio of 1:1.
The reduction in allele frequencies, and in the number of polymorphic sites within UTR pG4
sequences, indicate UTR pG4 are under heightened selective pressures compared to non-pG4
UTR regions. To place the degree of selection on UTR pG4s in context, we applied a mutabilityadjusted proportion of singletons (MAPS) metric, which measures the relative enrichment for rare
variation within a particular class of variants accounting for differences in mutation rates based on
local sequence context [37]. A similar approach has been recently used to assess the degree of
selective pressure against upstream open-reading frame-creating variation within 5’UTR variants
in the gnomAD database [46]. Within the canonical pG4 motif, we predicted that variants affecting
the central guanine of each G-tract should be most constrained, since biophysical studies of G4
stability have shown that mutations affecting the central tetrad (2nd guanine of each trinucleotide
guanine repeat) are most detrimental to secondary structure stability [76]. To remove the
ambiguity of which specific guanines are involved in secondary structure formation when more
than three guanines form a pG4 G-tract, we focused only on single nucleotide variants within
trinucleotide G-tracts (n = 3137). By examining variation across each pG4 G-tract, we found
central guanine positions within UTR pG4 G-tracts are consistently enriched for singletons (one
sequenced variant in gnomAD whole genomes) compared to non-pG4 UTR variants (Fig. 2.4,
permuted P<10-4). Notably, non-pG4 UTR variants reflected a similar degree of constraint as
synonymous coding variants, while central position guanines exhibit a similar degree of selective
pressure as missense variation in protein-coding regions of the genome. Interestingly, the most
proximal and distal 5’ and 3’ guanine of each trinucleotide pG4 G-tract demonstrated significantly
less enrichment of singleton variants within gnomAD across gene classes compared to central
guanine positions as determined by permutation testing (P-values = 0.0237 and 0.0022
respectively - Figure 2.15). This result suggests these positions are under less negative selection
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compared to central positions, perhaps because mutations in these positions can preserve the
potential for RNA to form non-canonical G4 2-quartets [63].

Figure 2.4: Mutability-adjusted proportion of singletons (MAPS) for each set of variants
affecting trinucleotide guanines within the meta-pG4 sequence motif. Central position
guanines consistently demonstrate the highest MAPS scores (are most constrained) compared to
non-pG4 UTR variants (permuted P < 1 × 10 ) across all contexts. Error bars represent the 5%
and 95% bootstrap permutations for each variant class. Purple-dashed line, orange dashed line,
and gray-dashed line represent MAPS score for Ensembl predicted high-impact coding (predicted
loss-of-function), missense, and synonymous mutations respectively.
−4

Finally, to provide additional control for our sequence context-derived mutability rates, we
compared the MAPS metric for UTR pG4 G-tracts to UTR trinucleotide G- and C-runs not
involved in pG4 formation. Although these non-pG4 G- and C-tracts exhibit modest enrichment
for rare variation at the central position, there is a significantly greater enrichment in singletons at
the central position of the UTR pG4 G-tract compared to non-pG4-forming contexts (Figure 2.15 -
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permuted P=0.0195). Thus, the excess rare variation is specific to the guanine within pG4 Gtracts most important for maintaining G4 secondary structure.

2.4: Most pG4 motifs in UTRs are isoform-restricted
Many functional UTR elements, including upstream open reading frames (uORFs), AU-rich
elements, and microRNA binding sites are frequently included in alternative 5’ or 3’ UTR isoforms
of the same gene [77,78]. Alternative UTR inclusion is hypothesized to significantly diversify the
number of possible post-transcriptional regulatory interactions for a given gene [79]. Given the
observed constraint over UTR pG4 sequences, we hypothesized that UTR pG4 sequences
should also exhibit patterns of alternative inclusion or exclusion.
To evaluate the extent of alternative UTR pG4 inclusion, we mapped UTR pG4s to protein-coding
transcripts for each gene in the Ensembl transcriptome database. Genes were considered to
produce constitutive UTR pG4 sequences when all annotated protein-coding transcript isoforms
contained at least one pG4, or alternative UTR pG4 sequences if at least one transcript isoform
lacked the pG4 sequence. Most constitutive pG4 genes were found to express UTRs with
identical pG4s across all transcript isoforms, however 36 of 620 5’UTR and 75 of 1275 3’UTR
constitutive pG4 genes produced transcript isoforms with non-identical pG4 sequences. For this
subset of non-identical pG4 transcript isoforms, approximately one-third differ by the addition /
subtraction of pG4 motifs (13/36 for 5’UTR, 20/75 for 3’UTR). Strikingly, we found that over half of
all genes producing UTR pG4 transcripts also encoded for alternative UTRs lacking pG4 motifs
(2254 genes with 5’UTR pG4 motifs and 1425 genes with 3’UTR pG4 motifs - Fig. 2.5).
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Figure 2.5: Distribution of 5’ and 3’ UTR transcript isoforms with constitutive or nonconstitutive pG4 sequence motifs. (a) Most genes with mRNA transcripts with UTR pG4
sequences also produce alternative isoforms lacking UTR pG4s (non-constitutive). (b)
Overrepresented biological processes for protein-coding genes producing both pG4 and non-pG4
5′ or 3′ UTR isoforms (n = 3148). GO-term enrichment was performed using PantherDB and
enrichment was determined by meeting a Benjamini–Hochberg adjusted P value cutoff of 0.05 by
Fisher’s exact test.
55

Indeed, of the 5235 total UTR pG4-containing genes, 3395 exhibited either alternative 5’ or 3’
UTR pG4 inclusion, and 284 produced UTRs with both alternative 5’ and 3’ pG4s. This
distribution of alternative and constitutive pG4 genes for each UTR context was found to be highly
significant through permutation testing (P-value<0.0001 for 5’ and 3’ UTRs). Moreover, MAPS
scores for alternative UTR pG4 indicate that their second guanine position is under a similar
degree of constraint as for all UTR pG4 and is comparable to that of missense variations for the
set of alternative pG4s found in genes with any disease association in ClinVar
(https://www.ncbi.nlm.nih.gov/clinvar/) (Fig. 2.4). As is the case for all UTR pG4, this second
guanine position was significantly more enriched for rare variation compared to either the 5’ or 3’
guanine (permuted P-value = 0.0138 and 0.004 respectively). Constitutive UTR pG4 sequences,
in contrast, do not show a similar pattern of selective constraint acting on the second G-tract
guanine, possibly because these sequences tend to be under less stringent selective pressures,
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or because we are underpowered to detect significant enrichment in rare variation. Notably the
MAPS metric for the central G-position of alternative pG4 sequence G-tracts remained
significantly higher than matched, non-pG4 G-tracts (permuted P=0.0124 - see Figure 2.15 for
comparison of constitutive pG4 G-tracts and other pG4 gene sets).
We next asked whether the expression of alternative pG4 isoforms tend to be restricted or shared
across different tissue contexts. Using transcript-isoform expression data across 45 different
tissues from GTEx, we find that many tissues appear to express both pG4 and non-pG4
transcripts simultaneously (Fig. 2.6). Notably, this simultaneous expression of both pG4 and nonpG4 isoforms also occurs in single-cell contexts (lymphocytes, fibroblasts), demonstrating that
this effect is not due to cellular heterogeneity in bulk tissue samples. Thus, most UTR pG4encoding genes express alternative isoforms which lack pG4 sequences, and that the
simultaneous expression of both pG4-isoforms and non-pG4 isoforms is widespread across
multiple tissue and cellular contexts.
To explore the functional associations of alternative UTR pG4 genes we performed a gene
ontology analysis. We find that these genes are frequently involved in dynamic intracellular
processes, including signal transduction, cellular responses to stress, and metabolic regulation
(Fig. 2.5b). In contrast, constitutive pG4 genes showed enrichment for biological processes
associated with the activation of gene expression in discrete temporal stages, including those
involved in tissue development, pattern specification, and cellular differentiation. These
observations, coupled with our finding that many tissues simultaneously express both pG4 and
non-pG4 isoforms of the same gene, suggests that isoform-switching between pG4-containing or
non-pG4 transcripts may facilitate dynamic cellular responses to external stimuli. More broadly,
our results demonstrate considerable variation in alternative pG4 inclusion within UTRs across
multiple tissue contexts, and suggest that the relative abundance of pG4 and non-pG4 UTRs may
be dynamically regulated within a given tissue.
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Figure 2.6: Median expression (TPM) of each pG4-transcript or non-pG4 transcript was
assessed for each tissue context. For the subset of genes producing UTRs with alternative
pG4 inclusion, both pG4-containing and non-pG4 isoforms are frequently expressed
simultaneously. Transcripts were considered as expressed if their median TPM measurement
exceeded one TPM for each tissue context considered. The proportion of pG4 genes expressing
both pG4 isoforms, and non-pG4 isoforms was then compared for each tissue.
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2.5: pG4 motifs in the 5’ and 3’ UTR are enriched for cis-eQTLs
We next evaluated the potential regulatory consequences associated with mutations affecting
UTR pG4s, hypothesizing that variants affecting pG4 sequences might also be more likely to be
associated with changes in gene expression. To test this hypothesis, we compared the proportion
of annotated cis-eQTLs versus non-eQTL SNPs identified by GTEx across pG4 and non-pG4
regions of the UTR, finding significant enrichment for either nominally significant or lead eQTL
variants (lowest P-value variant) in 5’ and 3’ UTR pG4 sequences compared to non-pG4 regions
of UTRs (Fig. 2.7). Notably, we continue to observe an enrichment of cis-eQTL variants in UTR
pG4 sequences using a reduced set of putatively causal cis-eQTLs [80], suggesting that
disruption of UTR pG4 sequences may cause changes in post-transcriptional regulation.
We next explored the direction of gene expression changes for UTR pG4 cis-eQTLs, considering
all variant-tissue effects separately for each significant variant-tissue interaction. We
hypothesized that variants affecting pG4 G-tracts are more likely to disrupt the structural integrity
of the RNA G4s, and thus might influence gene expression differently than variants affecting gap
(non-G-tract) sequences within pG4 motifs. Since the magnitude of normalized effect-size
estimates in GTEx has no direct biological interpretation, we compared differences in the
direction of variant effects across pG4 and non-pG4 sequences. As expected, UTR variants in
non-pG4 regions are not significantly biased towards increasing or decreasing gene expression,
regardless of whether the mutation affected a G-tract, or non-pG4 G-tract nucleotide. In contrast,
mutations affecting structurally important pG4 G-tracts in the 3’UTR tend to increase mRNA
expression compared to non-G-tract bases (OR 1.75, 95% CI: 1.34 to 2.30, P<3.0-5) - Fig. 2.8.
This relationship for the 5’UTR was not observed. Given the role of the 3’UTR in mediating mRNA
stability, the tendency for G-tract base mutations to increase gene expression suggests the
involvement of 3’UTR G4s in decreasing mRNA stability.
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Figure 2.7: Analysis of frequency of variants in UTR pG4 also being GTEx cis-eQTLs
compared to non-pG4 UTR variants. GTEx cis-eQTLs are enriched within UTR pG4 relative to
the number of tested (non-eQTL) SNPs when comparing lead SNPs, high-confidence causal,
nominally significant, and nominally significant in RBP-binding sites in matched UTR regions.
Error bars represent the 95% confidence interval for the odds ratio.

Figure 2.8: Annotated cis-eQTLs affecting 3’UTR pG4 sequences tend to increase gene
expression. Odds ratio for a cis-eQTL increasing gene expression across all cis-eQTL-tissue
effects (n = 379,441, P value < 2e−16, Fisher’s exact test), where the variant affects a pG4 G-tract
compared to those affecting gap sequences. Error bars represent the 95% confidence interval for
the odds ratio.
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2.6: RNA-protein binding sites are enriched over UTR pG4 regions
Transcriptome-wide RNA structure mapping studies have suggested that most RNA G4 are
unfolded in eukaryotes, but not in prokaryotes, leading to the hypothesis that intracellular factors
bind RNA G4s to maintain their unfolded state in cellulo [65]. To gain insights into regulatory
mechanisms mediating pG4 effects on gene expression we investigated the propensity of proteinbinding sites to overlap UTR pG4s by comparing the proportion of UTR pG4 sequences
overlapped by RNA-binding protein (RBP) binding sites published by ENCODE to non-pG4
forming regions of the UTR[81]. This data consists of cross-linking immunoprecipitation
sequencing (CLIP-seq) peaks, called from K562 or HepG2 cell lines for over 150 RBPs,
containing at least one highly reproducible (IDR = 1000) [82] binding peak within the 5’ or 3’ UTR.
When compared to non-pG4 regions of the UTR, the frequency of overlap between unique (nonoverlapping) RBP binding sites and pG4 sequences was almost 6-fold (P<<2.2x10-16, Chisquare test) higher compared to non-pG4 sequences in the 5’UTR (Fig. 2.9). Enrichment of RBP
binding locations over pG4 sequences within the 3’UTR was markedly higher (14-fold,
P<<2.2x10-16, Chi-square test). Given the enrichment within UTR pG4s for cis-eQTLs and
protein binding sites, we tested for significant colocalization between these two features in pG4s.
Taking the subset of pG4 regions overlapped by any protein binding sites, we examined the
density of cis-eQTLs in UTR pG4 regions also overlapping CLIP-seq peaks. When all nominally
significant cis-eQTLs are considered, we observe a significant enrichment of cis-eQTLs in the
3’UTR that are also protein binding sites (Fig. 2.7), indicating that variation in 3’UTR pG4
sequences may influence gene expression through changing RNA-protein interactions.
Given the observed association between protein binding sites and pG4 sequences, we next
asked whether specific proteins’ binding sites are enriched for pG4s. For each protein, we
determined the proportion of protein-specific binding sites containing pG4 sequences, against the
total background rate of all CLIP-seq binding sites containing pG4 sequences. To determine a
significant overrepresentation of pG4 sequences within a given protein’s binding sites, we
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performed a hypergeometric test against the null hypothesis that there is no overrepresentation of
pG4 binding sites within the set of a protein’s binding sites - Fig. 2.9.

Figure 2.9: Density of RBP-binding sites per kilobase of pG4 sequence compared to nonpG4 regions of the UTR. pG4 sequences are more frequently overlapped by RBP binding sites
compared to non-pG4 sequences within the UTR (P value ≪ 2.2 × 10 , chi-square test).
−16

This analysis revealed enrichment for proteins that have been implicated in RNA G4 binding
(GRSF1, FUS), and those that, to our knowledge, have not previously been associated with RNA
G4 structures (PRPF4, GTF2F1, and CSTF2T). GRSF1 is a cytoplasmic protein involved in viral
mRNA translation and has recently been shown to play a role in the degradation of G4-containing
RNAs in mitochondria [83,84]. Other proteins with significant enrichment for pG4 binding include
those involved in mitochondrial processes (FASTKD2), transcriptional activation (GTF2F1),
mRNA transport (FAM120A), mRNA degradation (XRN2, UPF1), in addition to several proteins
implicated in RNA polyadenylation and splicing (CSTF2T, PRPF4, RBFOX2), and surprisingly,
micro-RNA (miRNA) biogenesis (DCGR8, DROSHA). Interestingly proteins demonstrating a
preference for binding UTR pG4 sequences tend to bind both 5’ and 3’ UTR contexts, with 14 out
of 20 proteins’ binding peaks showing enrichment for overlap over 5’ and 3’ pG4 sequences in
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HepG2, and 17 out of 25 for K562 independently. Taken together, these data suggest that RBP
binding is enriched in UTRs over pG4 sequences, and that RBP-pG4 interactions may regulate
gene expression.
An analysis of gene expression changes with sh-RNA knockdown for the majority of pG4enriched binding proteins showed genes containing pG4 in either the 5’ or 3’ UTR are much more
likely to be significantly differentially expressed compared to non-pG4 genes (Figure 2.16).
Approximately one-third of the proteins exhibiting a binding preference for UTR pG4 change the
expression of pG4-containing genes concordantly across K562 and HepG2 cells (GTF2F1,
FASTKD2, UPF1, NONO, GRSF1, NCBP2, AKAP8L, DDX6, FKBP4, TAF15, LARP4). Of these
11 RNA-binding proteins, knockdown of eight tends to decrease expression of UTR pG4 genes
(GTF2F1, UPF1, NONO, GRSF1, NCBP2, AKAP8L, DDX6, LARP4), while knockdown of three
(FASTKD2, FKBP4, TAF15) tends to increase their expression, suggesting that most of the
proteins enriched for pG4 binding tend to increase, or stabilize RNA expression rather than
facilitate their degradation. This result is consistent with our finding that cis-eQTLs affecting
3’UTR pG4 sequences are more frequently associated with decreasing gene expression.
Finally, to explore the potential existence of post-transcriptional regulatory networks relying on
shared RNA G4-protein interactions, we tested for a significant overlap in pG4 containing
transcripts targeted by each protein enriched for pG4 binding interactions. Taking the set of 31
proteins with significant overrepresentation for pG4 binding (Bonferroni-corrected P<0.001) and
at least 20 unique pG4 binding sites in HepG2 or K562, we assessed overlaps between the
various proteins’ pG4 gene targets (Fig. 2.10). We found low overlap of targets in helicases that
have been hypothesized to bind RNA G4s frequently, such as DDX6, DDX51, and DDX52. In
contrast, we find a subset of G4-binding proteins sharing a significant degree of overlap in G4gene targets, including FASTKD2, FAM120A, CSTF2T, PRPF4 and GTF2F1, none of which have
been shown to bind RNA G4 structures previously. These data point to possible mechanisms of
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gene control relying on the shared interactions of these proteins with their respective RNA
targets. Indeed, assessing the functional associations of 133 pG4 genes sharing at least 3 out of
5 protein-binding interactions from this module revealed enrichment for genes involved in viral
process (GO:0016032, FDR-adjusted P=0.0268), suggesting that these genes and putative pG4
binding proteins, may be involved in mediating host-viral interactions within the cell.

Figure 2.10: Enrichment of specific protein–pG4 binding sites using CLIP-seq data from
ENCODE. a, b Enrichment of specific proteins over pG4-binding sites within the 5′ UTR (left) and
3′ UTR (right)—red line corresponds to P = 0.0001 (hypergeometric test). c, d Heatmaps depicting
the significance of overlap (hypergeometric −log P value) in pG4 gene targets for proteins found
to bind pG4 sequences preferentially.
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2.7: 3’UTR pG4 in disease-causing genes are enriched for variants
Multiple studies assessing evolutionary constraints in protein-coding regions of the human
genome have shown that regions depleted of genetic variation are also enriched for pathogenic
variation [85–87]. Under the principle that purifying selection removes deleterious variants from
the genome to produce regions depleted of genetic variation, we expect UTR pG4s should also
be enriched for pathogenic variation. Since pathogenic variants in ClinVar are overwhelmingly
annotated in protein-coding regions of the genome, we are underpowered to test for a direct
association between the set of annotated pathogenic variants and UTR pG4 sequences. Instead,
we asked whether potentially pathogenic variation in ClinVar is enriched within UTR pG4
sequences in known disease-associated genes. To test this hypothesis, we mapped all single
nucleotide variants annotated in the most recent release of the ClinVar database available at the
time of this writing [88] (April, 2019) across UTRs, and compared their relative density in pG4
versus non-pG4 sequences in disease-associated genes. We defined the set of diseaseassociated genes as any gene with at least one variant having an annotated as Pathogenic or
Likely Pathogenic in ClinVar, excluding variants with an annotation of Benign or Likely_benign. To
maximize our power for this analysis, we expanded our set of rG4-seq G4s to include all noncanonical G4-forming sequences mapped and reported by rG4-seq in HeLa cells [63]. We found
modest enrichment for variation in 3’UTR pG4 sequences, rG4 3’UTR sequences, and a notable
enrichment in 3’UTR pG4 sequences within annotated RBP binding sites from ENCODE in
disease-associated genes compared to non-pG4 forming regions of the 3’UTR - Fig. 2.11a (All
pG4: OR 1.51, 95% CI 1.20-1.88, P<0.0005, rG4-seq pG4: OR 1.18, 95% CI 0.98-1.42, P=0.067,
RBP pG4: OR 6.01, 95% CI 3.87-8.91, P<5e-12 - Fisher’s Exact Test). In contrast, there was only
evidence for enrichment of variants in the 5’UTR rG4 sites (OR 2.32, 95% CI 1.93-2.78,
P<2.25x10-16 Fisher’s Exact Test), but not pG4 or pG4-RBP overlap regions. It is important to
note though that the above statistical test only contrasts relative enrichment of putative
pathogenic variants in pG4 vs. non pG4 UTR sequences. Thus, the lack of such relative
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enrichment in the 5’ UTR may reflect the generally greater density of other functional elements
within 5’UTR sequences. In conclusion, these data imply that disease-associated noncoding
variation may be enriched in 3’UTR pG4 regions.
Finally, we tested for enrichment of common variants that have been associated with disease
phenotypes using annotations available in the NIH GWAS Catalog (April 2019). There were not
enough GWAS-associated lead variants within UTR pG4 regions to detect enrichment (7 variants
in 5’UTR pG4, 4 in the 3’UTR pG4). However, given the enrichment for cis-eQTLs in UTR pG4,
we hypothesized that disruption of UTR pG4 sequences could affect post-transcriptional
mechanisms regulating gene expression, thus providing a potential mechanistic link between
GWAS variants and their observed phenotypes. To test this hypothesis, we assessed evidence of
allelic imbalance at select GWAS SNPs either falling within a UTR pG4 region, or in high LD with
a common SNP (r-squared > 0.85 in the GBR population of 1KG) falling within a UTR pG4 in
GTEx. Despite being limited by the number of heterozygous individuals in GTEx with matched
whole-genome sequencing available, our analysis uncovered several proxy SNPs in high LD with
GWAS tag-SNPs (Figure 2.18), and one GWAS lead variant exhibiting evidence of significant
allelic imbalance. The lead GWAS variant, rs1048238 is a common SNP within the 3’UTR of
HSPB7, a chaperone protein that is highly expressed in heart and skeletal muscle and has been
associated with hypertension in a recent GWAS [89,90] (Fig. 2.11b). We found that rs1048238
exhibited a substantial imbalance of reads mapping to the alternative allele in 84 heterozygous
individuals, even after correcting for read-mapping biases using WASP-filtering [91]. Taken
together, these results demonstrate that the predicted pG4-disrupting variant is associated with
increased expression of the alternative allele at this locus (Fig. 2.11c-d). This association is
consistent with our previous observations from transcriptome-wide mapping of pG4 eQTL
showing that 3’UTR pG4 eQTLs tend to increase gene expression (Fig. 2.9) and suggest that the
impact of these variants on gene expression are responsible for their respective GWAS
associations.
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Figure 2.11: UTR pG4 sequences are enriched for known pathogenic, and putative
disease-associated genetic variants. (a) Annotated variants within ClinVar disease-associated
genes occur with greater frequency in UTR pG4 sequences compared to non-pG4 UTR regions
in the 3′ UTR across multiple G4 subsets (error bars represent the 95% confidence interval). (b)
rs108348 maps to a 3′ UTR pG4 G-tract guanine within the primary HSPB7 transcript, which is
encoded on the negative DNA strand. The SNP disrupts the canonical G4 sequence motif by
causing a G to A mutation in the RNA transcript. (c, d) WASP-mapping of allele-specific reads in
84 GTEx skeletal muscle samples reveals significant allelic imbalance favoring expression of the
alternative allele (P value < 1 x 10 , likelihood ratio test). Boxplot in c represents median and 1.5
times the interquartile range of WASP-aligned RNA-seq reads aligning to the ference (red) or
alternative (blue) allele.
−100
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2.8: Summary and future directions
We have applied a deep catalog of human genetic variation to assess evolutionary pressures
over putative G-quadruplex forming sequences within 5’ and 3’ UTRs. We hypothesized that if
these regions are functionally important they should be depleted of variation. Supporting this
hypothesis, we show that variation within UTR pG4 sequences is reduced compared to non-pG4
UTR regions using a local sequence context based substitution model. Moreover, our analysis of
positional constraint within the meta-pG4 motif reveals selective pressures acting on central
guanines of each trinucleotide G-tract comparable to that of missense mutations in protein-coding
regions of the genome. These findings are consistent with in vitro biophysical studies of DNA Gquadruplex stability, which have shown that central position substitutions are most destabilizing,
and consequently were predicted to be the most deleterious for native biological functions of G4s
[76,92,93]. Interestingly, we find that non-central guanines appear less constrained compared to
central positions - possibly because mutations at these positions may preserve the potential for
RNA to form non-canonical G4 2-quartets. Indeed, these G4 2-quartets have been estimated to
account for 1/4 to 2/3 of all RNA G4 structures observed by transcriptome-wide rG4-seq in HeLa
cells [63].
We also uncover a greater proportion of cis-eQTLs mapping to pG4 regions compared to nonpG4 sequences within both 5’ and 3’ UTRs. Our analysis of nominally-significant cis-eQTL
enrichment in UTR pG4 sequences may be confounded by the presence of linked SNPs that
reach nominal significance because of their proximity to causal eQTL SNPs, however this likely
deflates our estimates of enrichment in UTR pG4 sequences because the relatively smaller size
of pG4 motifs (15 - 33nt) makes multiple linked nominally significant cis-eQTLs more likely to
occur along the length of non-pG4 UTR regions. Nevertheless, the enrichment of cis-eQTLs
within UTR pG4 remain unchanged when we limit each UTR pG4 feature to contain at most 1
nominally-significant cis-eQTL SNP.
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Using CLIP-seq data for over 150 proteins published by ENCODE, we find 15 proteins whose
binding sites are enriched for pG4 sequences across two cell lines, and identify regulatory
modules associating a set of RNA binding proteins, including FAM120A, FASTKD2, and CSTF2T,
with pG4 gene targets involved in viral mRNA expression. Indeed, several examples of viral hijacking of eukaryotic RBPs have been reported in the literature [94,95], and G4-forming
sequences have been found to occur commonly in multiple viral genomes [96]. This, coupled with
the observation that RNA G4s appear to be universally depleted within prokaryotic transcriptomes
[65], suggests that viruses might rely on G4s as a mechanism for co-opting host cell machinery
involved in gene expression and RNA regulation.
There are three primary limitations to the current study. First, we applied a text-based approach
towards identifying regions of putative G-quadruplex formation within RNA UTRs. Although this
approach has been commonly employed in previous work [63,72], there exists a considerable
literature regarding possible variations to the canonical G-quadruplex forming sequence and
methods that capture more variable motif definitions [97,98]; [99]. Given the comparably limited
evidence that many of these alternative G-quadruplex sequences form readily in cellulo we used
a more stringent motif definition, but alternative G4 sequences will have been missed in our
analysis. The modest enrichment in singletons at the central position of trinucleotide G- and Ctracts not matching our canonical pG4 sequence motif is consistent with this possibility. Thus, our
assessment of sequence constraint and functional enrichment within UTR G4 forming regions is
likely incomplete. Secondly, although we have uncovered evidence suggesting G4 secondary
structure formation is constrained, whether these pG4s form secondary structures in vivo remains
unclear. Finally, our assessment of selective pressures acting across UTR pG4 sequences using
the MAPS metric is limited in power by low variant numbers. Nevertheless, we report multiple
lines of evidence supporting the biological importance of putative secondary structure-forming G34

quadruplexes within UTRs. Although RNA UTRs represent only a small fraction of the noncoding
genome, they are core components involved in mediating post-transcriptional regulation of gene
expression. Ultimately, we hope this work will motivate researchers to consider G4s and other
RNA elements in UTRs when assessing the possible impact of genetic variations in human health
and disease.
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2.9: Supplementary Materials to Integrative analysis reveals RNA G-Quadruplexes are
selectively constrained and enriched for functional associations

Figure 2.12: Distribution of binned distances for mapped canonical 5’ (left) and 3’ (right)
UTR pG4 sequences with respect to protein-coding sequences across pG4-UTR
containing mRNA transcripts. The relative locations of pG4 sequences within UTRs are plotted
(x-axis), with 0 being adjacent to the coding sequence, and 1 representing the full-length of the
annotated UTR away from the CDS.

Figure 2.13: Quantile-quantile plot showing matching between pG4 and non-pG4
containing transcripts based on LOEUF scores for 5’UTR (left) and 3’UTR (right)
transcripts. Allele frequencies (Figure 1b) and substitutions (Figure 1c) were compared across
constraint-matched transcripts using gnomAD’s LOEUF metric to control for the possibility that
nearby constrained coding sequences might affect local allele frequency estimates. LOEUF
scores for non-G4 transcripts plotted on the X-axis and LOUEF scores for G4-containing
transcripts are plotted on the Y-axis.
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Figure 2.14: The empirical distribution of observed vs. expected number of substitutions
across 10,000 bootstrapped 5’ and 3’ UTR regions in the European subpopulation of the
1000 Genomes Project Phase 1 release. Red dotted line indicates the observed vs. expected
ratios estimated by applying the noncoding heptamer mutation model across 5’UTR and 3’UTR
pG4 sequences respectively.
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Figure 2.15: MAPS scores for All (black), G4 (red), and non-G4 GGG/CCC (blue) variants
across multiple gene sets. Error bars represent 90% CI from 10,000 bootstraps.Top ⅓ LOEUF
represent MAPS scores for pG4 versus non-pG4 variants within the top-1/3rd most constrained
genes as estimated by the gnomAD LOEUF metric. Alt. pG4 represent alternatively included pG4
sequences while Const. pG4 represent constitutively included pG4 sequences. ClinVar pG4
sequences are those pG4 within UTRs of disease-associated genes in ClinVar. Permutation Pvalues for the second guanine of each trinucleotide G-tract context compared to non-pG4 Gtracts in UTRs are: P=0.0195 for all UTRs, P=0.1063 for Top ⅓ LOEUF, P=0.0124 for Alt. pG4,
P=0.4653 for Const. pG4, and P=0.0579 for ClinVar pG4. Genome-wide MAPS scores for
synonymous (grey), missense (orange), and putative loss of function (red) protein-coding
variation shown as dotted lines.
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Figure 2.16: Distribution of odds ratio with error bars representing 95% confidence interval
for changing gene expression of a pG4 containing gene versus a non-pG4 containing gene
with sh-RBP knockdown in ENCODE as determined by Fisher’s Exact Test. Results for
HepG2 (a) and K562 (b) are shown. Colors represent a tendency for an RBP-knockdown to
increase the expression of pG4 containing genes (blue), decrease their expression (red) or have
no effect on changing the expression of pG4 genes (grey) at an FDR < 0.001. Proteins having the
same direction on changing pG4 gene expression across both HpeG2 and K562 cell lines are
marked by an asterisk.
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Figure 2.17: Boxplot of distribution of distances between 5’ UTR (a) and 3’UTR (b) pG4
sequences and nearest annotated protein-coding exons in ClinVar disease-associated
genes showing the 1.5 times the interquartile range and median values. Compared to
randomly selected positions within non-pG4 5’ and 3’ UTRs of ClinVar disease-associated genes,
UTR pG4 sequences tend to be located further away from protein-coding exons.
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Figure 2.18: Additional common SNPs in high LD (r > 0.85 in the 1000 Genomes GBR
population) with GWAS tag SNPs exhibiting evidence of allelic imbalance in UTR pG4
sequences. rs352047, rs77247684, and rs761153 affect 3’UTR pG4 sequences. rs11864750
affects a 5’UTR pG4 sequence.
2
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CHAPTER 3: DISRUPTING UPSTREAM TRANSLATION IS ASSOCIATED WITH
LOSS-OF-FUNCTION IN HUMAN DISEASE*

3.1: Ribosome profiling and non-canonical open reading frames
With the completion of the human draft genome sequence, elucidating the number of proteincoding genes represented a major challenge. While searching for known homologs using existing
gene databases could help map the locations of known protein-coding sequences in the human
genome, these strategies depended on the completeness of existing databases and the degree
of evolutionary relatedness between humans and other species [100]. Naive approaches to
mapping protein coding sequences relied on identifying sequence stretches that could
correspond to open reading frames (ORFs) based on the amino acid code. These techniques
identified sequence stretches consisting of first identifying an upstream start codon, and scanning
along the DNA sequence in search for an in-frame downstream TGA, TAG, or TAA stop codon.
Under the assumption that the DNA has a random sequence, and ~50% GC-content, a
trinucleotide stop sequence is expected to appear once every 64 base pairs. Putative proteincoding ORFs could therefore be identified if they extended significantly beyond this expected
length. Crucially, ORFs smaller than 64 base pairs could not be distinguished from background
nucleotide distributions and therefore could not be annotated as functional with certainty. While
this ORF-scanning approach could be used to identify almost all the known protein-coding genes
in prokaryotes, the increased size and widespread presence of introns of the eukaryotic genome
presented significant challenges.
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To address these challenges, several refinements to the basic ORF-scanning approach were
proposed. These included using biased codon distributions of known protein-coding regions of
the genome to assess new putative ORFs, identifying exon-intron boundaries using known splicesite motifs, and matching putative genes to upstream regulatory sequences including CpG islands
that typically mark the beginning of protein-coding genes [100]. Although these strategies
significantly improved computational ORF mapping from human DNA sequence alone, lowthroughput experimental validation remained indispensable to ascertaining whether predicted
ORFs were truly capable of producing endogenous protein products.
Annotation of ORFs using direct experimental evidence of ribosome translation is now possible
through high-throughput ribosome profiling. Ribosome profiling is an experimental technique that
produces a global, quantitative snapshot of actively translating ribosomes throughout the cell
[101]. The typical experimental workflow involves treating cells with compounds that inhibit
translational elongation and immobilize translating ribosomes on RNA transcripts. These RNAs
are extracted and digested using nucleases that remove RNA fragments unprotected by the
presence of immobilized ribosomes. After digestion, ribosomal RNA (rRNA) is depleted, and the
remaining ribosome-protected fragments are sequenced and re-aligned to the genome (Fig
3.1). Because translation elongation proceeds with a 3-nucleotide periodicity, this feature can be
combined with others to computationally annotate putative ORFs throughout the transcriptome
[101,102].
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Figure 3.1: Basic experimental workflow for ribosome profiling.

3.2: Pervasive translation in non-canonical open reading frames
The unanticipated abundance of ribosome-protected fragments mapping outside of known
annotated protein-coding regions of the genome was a key observation arising from early
ribosome-profiling studies [102–104]. When mapped back to the genome, many of these
fragments shared similar characteristics to ribosome-protected fragments in known coding
regions of the genome, including size distribution and 3-nucleotide periodicity [105]. Together,
these studies suggested that cellular RNAs previously not thought to encode for functional
proteins or peptides were nevertheless being translated by ribosomes. As many of these newly
mapped non-canonical ORFs (ncORFs) were short in length, some suggested that they could
encode for functional micropeptides which had been previously overlooked in ORF mapping
studies due to biases favoring ORF annotation with longer sequence lengths [104–107].
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Early examples of functional micropeptides had been characterized in the literature prior to their
being identified in ribosome profiling data. Early evidence of micropeptide functionality was first
characterized in yeast, where mutagenesis studies of 247 small ORFs <100 amino acids in length
identified 22 ORFs required for haploid growth [108]. Specific functional small ORFs were further
characterized from studies in Drosophila using polysome profiling - a technique which involves
fractionating cellular mRNAs in a sucrose gradient to extract species bound by multiple
ribosomes - which identified that select noncoding RNAs without obvious coding potential could
be enriched from polysome-bound fractions [109]. Among these early examples of translated
noncoding RNAs, the tarsal-less (tal) gene transcript was found to encode 4 small ORFs capable
of producing 11-amino-acid-long peptides indispensable for early Drosophila morphogenesis
[109]. Further investigation of polysome-bound noncoding RNAs from Drosophila identified a
second polycistronic noncoding RNA (pncr003:2L) encoding two ORFs of length 28 and 29 amino
acids each producing peptide products involved in regulating cardiac calcium transport [110].
Together these functional micropeptides served as early evidence that length-biases in gene
discovery pipelines may have overlooked an entire class of functional elements encoded within
sequenced genomes.
To date, several additional examples of functional micropeptides in the human genome have
been reported. These include several micropeptides implicated in regulating intracellular calcium
levels and muscle contraction [111–113], the inflammatory response [114,115], and cellular
metabolism [116–120]. Although modern ribosome-profiling approaches have uncovered
widespread evidence translation in thousands of small non-canonical ORFs (ncORFs) in the
human genome [102,121,122], what fraction of these ncORFs (ncORFs) can produce functional
micropeptides remains an open question.
A second possibility is that translation of ncORFs serve regulatory rather than coding functions.
This regulatory hypothesis is most strongly supported by studies of upstream open reading
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frames (uORFs). Since uORFs can initiate translation by ribosomes prior to their reaching
downstream coding sequences (CDS), they are most frequently associated with repressive
effects on downstream CDS translation [122–124]. Moreover, it has been observed that cisregulatory relationships between uORFs and downstream coding sequences are frequently
maintained across species, but the nucleotide content of these ORFs are not [122,125]. Together,
this evidence implies that the functional importance of uORF translation is in its regulatory effect
on downstream protein expression rather than micropeptide encoding. Nevertheless, a few
examples of uORF-encoded micropeptides which are capable of repressing downstream
translation initiation at the CDS in a peptide-dependent have also been observed, although this
phenomenon appears to be the exception rather than the rule [126,127]. More recently, the
striking pervasiveness of translation outside of canonical protein coding ORFs revealed by
ribosome profiling has not stopped some from speculating that micropeptides resulting from
ncORF translation are broadly functional [107].

3.3: Disrupting upstream translation in mRNAs is associated with loss-of-function in
human disease
The classic view of information processing in the cell by gene expression occurs through
transcription followed by translation. This basic flow is often complicated by regulatory elements
which confer additional stages of processing and control. In particular, upstream open reading
frames (uORFs) are segments of 5’UTR mRNA sequences that can initiate and terminate
translation upstream of protein-coding start codons. Specific uORFs are known to control protein
expression by tuning translation rates of downstream protein-coding sequences, and potential
uORFs have been identified in ~50% of all human protein-coding genes [123,128].
Translation initiation is the rate-limiting step controlling post-transcriptional gene expression [129],
and rates of translation initiation can significantly impact mRNA stability [130–134]. Cap46

dependent translation initiation begins when the 40s ribosomal subunit encounters a start codon
as it scans along the 5’UTR. At the start codon, the 40s subunit acquires the 60s subunit with
other translation initiation factors and peptide synthesis begins. Scanning ribosomes
encountering uORFs may prematurely initiate translation in the 5’UTR; if this occurs, upon
reaching the uORF termination codon the ribosome may dissociate from the mRNA transcript, or
the 40s subunit may resume scanning after the 60s subunit is lost. Resumption of scanning leads
to translation of downstream reading frames only if the necessary translation initiation factors are
reacquired by the 40s subunit before reaching the downstream start codon. Thus, the spatial
combination of uORFs and protein-coding start codons can produce different effects on
translation of the downstream gene.
Previous analyses of large-scale population data have shown that genetic variants creating new
uORFs are rare, suggesting that these variants are subjected to strong negative selection due to
their capacity to cause pathogenic loss-of-function of associated proteins [123,135]. Moreover, it
has been shown that variants destroying stop codons in translated uORFs are under strong
negative selection, presumably because the resultant translational readthrough can decrease
start codon recognition and translation initiation at the coding sequence (CDS) [46]. In contrast,
less is known about the impact of genetic variation within translated uORFs. Furthermore, recent
untargeted ribosome-profiling experiments have revealed striking evidence of active translation at
thousands of uORFs throughout the genome, but the biological significance of this phenomenon
remains unresolved [123].
Here we use translated uORFs mapped through ribosome-profiling experiments and a deep
catalogue of human genetic variation to characterize patterns of selection acting on single
nucleotide variants (SNVs) in translated uORF sequences. We assess evidence for the functional
importance of translation at uORFs, and explore possible phenotypic consequences associated
with genetic variation in these sequences. Using the allele frequency spectrum of SNVs from
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71,702 whole genome sequences in gnomAD, we find that SNVs introducing new stop codons, or
creating stronger translation termination signals in uORFs are under strong selective constraints
within 5’UTRs. We propose that these variants are under selective pressure because they disrupt
translation initiation at downstream protein-coding sequences. We then utilize the Penn Medicine
Biobank (PMBB) to discover new, robust disease-gene associations using uORF stop-creating
and stop-strengthening variants and replicate these associations in the UK Biobank (UKB), and
by gene burden tests aggregating rare protein-coding loss-of-function variants. Finally we validate
the impact of uORF stop-creating and stop-strengthening variants on protein expression for our
top phenome-wide significant associations. These data demonstrate that mutations in translated
uORFs creating new stop codons, or strengthening existing stop codons can contribute to
disease pathology by changing protein expression.

3.3: Variants introducing new stop codons in uORFs are under strong negative selection
Since elongating ribosomes must translate uORFs before they reinitiate translation at the CDS,
we hypothesized that genetic variants introducing new stop codons in translated uORFs could
impede downstream translation initiation. Because these variants interrupt translation without
affecting the coding sequence directly, we term them upstream termination codons (UTCs) to
distinguish them from premature termination codons within protein-coding sequences.
To estimate the deleteriousness of UTC mutations, we assessed their frequency spectrum in
gnomAD using the Mutability-Adjusted Proportion of Singletons (MAPS) metric. MAPS compares
the strength of selection acting against different classes of functional variation by assessing the
relative enrichment for rare singleton (one sequenced allele) variants in gnomAD, adjusted for
local mutation rates (see Appendix B). More deleterious groups of SNVs - including premature
termination codons and essential splice site mutations - show greater enrichment in singletons in
gnomAD, and consequently have higher MAPS scores. MAPS has previously been used to
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assess patterns of selective pressures acting on different classes of variation in both proteincoding and non-coding regions of the genome [37,45,135–138].
Using translated uORFs from 4392 genes identified by deep ribosome profiling of two human cell
lines (Figure 3.11) [94], we mapped genetic variation from 71,702 whole-genome sequences in
gnomAD (version 3)[91]. We identified the subset of UTC mutations by selecting SNVs which
mutated uORF codons to either UGA, UAG, or UAA in the mapped uORF reading frame (Figure
3.2a). We calculated MAPS scores for these UTC mutations, finding that they are under strong
negative selection within 5’UTRs, comparable to that of missense mutations in canonical proteincoding regions of the genome (Figure 3.2b). Indeed, MAPS scores for these variants are
significantly higher than all uORF variants (Figure 3.2b, P<0.001), sets of uORF variants matched
by their underlying trinucleotide mutation context (Figure 3.12, P<0.001 - see Appendix B), all
5’UTR variants creating UTCs outside of mapped translated uORFs (P=0.0441), and stopcreating variants in ORFs in 3’UTRs, translated pseudogenes, and lncRNAs also mapped by
ribosome-profiling from the same study (Figure 3.2b P=0.0041, Figure 3.11). Intriguingly, MAPS
scores were highest for variants predicted to introduce strong (UAA) stop codons that are less
susceptible to translational read-through [95–97]. In contrast, variants introducing the weaker
UGA stop codon exhibited MAPS scores that are only nominally higher than MAPS scores for all
uORF variants (P = 0.2833), suggesting that they may be less deleterious by comparison. To
account for the possibility that the heightened MAPS scores for UTC mutations resulted from
overlap between 5’UTRs and annotated coding sequences in different mRNA isoforms, we
repeated this analysis excluding all uORF variants overlapping with any annotated CDS
sequence. Re-calculated MAPS scores with all CDS-overlapping variants removed remained
essentially unchanged (Table 3.2), ruling out the possibility that the enrichment in rare variation
for UTC mutations is driven by selection on coding sequences. Additionally, we previously
observed that variants destroying the central guanine of putative G-quadruplex forming
sequences exhibit heightened MAPS scores in UTRs. We repeated this analysis with all potential
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G-quadruplex disrupting variants (n = 57) excluded, seeing a negligible effect on MAPS scores
for all UTC mutations (MAPS = 0.0377, 95% CI: 0.0196-0.0557). Overall, the strong selective
pressure to remove UTC mutations implies that these variants are also more likely to have
functional biological consequences.

Figure 3.2: Stop-introducing and stop strengthening mutations in translated uORFs are
under strong negative selection. (a) Examples of possible stop-gained (UTC) or stopstrengthened mutations in translated uORFs. (b) Mutability-Adjusted Proportion of Singletons
(MAPS) scores for different classes of stop-introducing mutations within translated uORFs. Grey,
orange, and purple dashed lines represent MAPS scores for synonymous, missense, and
predicted loss-of-function (pLOF) SNVs affecting canonical protein-coding sequences in
gnomAD. (i) MAPS scores for non-uORF variants including all 5’UTR SNVs, stop gained
mutations in ncORFs, and all 5’UTR stop gained mutations (ii) MAPS scores for all uORF SNVs
and stop gained mutations in uORFs show that uORF UTC mutations are significantly enriched
for singletons. This is also observed for UAA-creating, and stop-strengthening SNVs in translated
uORFs. Error bars represent bootstrapped 90% confidence intervals.

3.4: Translated uORFs use weak stop codons
Stop codons have different translation termination efficiencies in both prokaryotes and
eukaryotes, with the hierarchy following the general pattern of UAA > UAG > UGA [139,142,143].
Given the observed selection against UTC mutations in translated uORFs, and in particular
against UAA-introducing variants, we next asked whether stop codon usage by translated uORFs
is distinct from the background distribution of UGA, UAG, and UAA trinucleotides in 5’UTRs. To
perform this comparison, we determined the relative frequency that UGA, UAG, or UAA
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trinucleotide sequences appeared within non-translated 5’UTR sequences, and compared this
frequency to the distribution of stop codons used in translated uORFs. To further control for the
possibility that translated-uORF containing UTRs might have significantly different background
nucleotide distributions, we also assessed the relative frequency of UGA, UAG, or UAA
trinucleotides from uORF-containing UTRs with translated uORF sequences excluded. Strikingly,
we find that translated uORF stop codons are significantly depleted of UAAs compared to
background UTR distributions (Figure 3.3a), suggesting that weaker stop-codons (UGA, UAG)
are preferred (permutation P<0.001 compared to all UTRs, P<0.001 compared to uORFcontaining UTRs). Indeed there are approximately 45% less uORF UAA stop codons compared
to the relative frequency of UAA trinucleotides in adjacent untranslated UTR sequences (uORFUAA=19%, matched UTR-UAA=35% - Table 3.3). In contrast, UGA stop codons are enriched
within translated uORFs compared to non-translated UTR sequences (permutation P<0.001
compared to all UTRs, P<0.001 compared to uORF-containing UTRs).

Figure 3.3: Translated uORFs tend to use weak stop codons. (a) Relative frequencies of
trinucleotides used as uORF stop codons compared to untranslated regions of uORF-containing
5’UTRs, or all 5’UTRs shows uORFs are significantly enriched for weaker (UGA, UAG) stop
codons and depleted of the UAA stop codons compared to control sequences. Error bars
represent 95% bootstrapped confidence intervals. (b) Proportion of strongly conserved (phyloP >
2) bases by phyloP scores from 100-way vertebrate alignments for uORF stop-creating, nonuORF stop-creating in uORF-containing UTRs, and non-uORF stop-creating in all UTR genomic
positions. Error bars represent 90% bootstrapped confidence intervals.
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Given the depletion of UAA-stop codons in translated uORFs, we next asked whether variants
changing weaker stop codons (UGA, UAG) to UAA were also enriched for singletons. Compared
to synonymous and missense variation within the protein-coding genome, we find that the MAPS
metric for stop-strengthening variants is significantly higher (Figure 3.2b-ii). This difference
remained significant compared to uORF variants matched by trinucleotide context, indicating that
this effect is specific to uORF stop codons (P=0.012, Figure 3.12). Given that UAA codons can
facilitate greater termination efficiency and more rapid ribosomal dissociation from mRNAs
compared to UAG and UGA codons [139,144,145], these results are consistent with the
possibility that stronger stop codons in uORFs can also increase the efficiency of translation
termination in the 5’UTR. Thus, like UTC mutations, stronger stop codons in uORFs may be
disfavored because they decrease the probability that ribosomes reinitiate translation at
downstream coding sequences.

3.5 Genomic positions that can create new stop codons in uORFs are conserved
Since the power of MAPS estimates are limited by the number of variants observed in gnomAD,
we assessed the evolutionary conservation of each possible uORF stop-creating position as
complementary evidence for their functional significance. For this, we compared the distribution of
phyloP scores across potential uORF-stop-creating positions derived from the UCSC 100-way
phyloP vertebrate alignment [38].. Specifically, for each potential new stop site, we compared the
proportion of genomic positions with a phyloP score of > 2 - corresponding to strong conservation
across multi-vertebrate alignment - versus those positions that were not strongly conserved
(phyloP < 2). A similar approach has been used to show that genomic positions with the potential
to produce new uORFs are strongly conserved across vertebrates [135].
We performed several assessments of phyloP scores across 5’UTR contexts. Consistent with our
MAPS analysis, potential stop-creating positions in translated uORFs are also more likely to be
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conserved compared to UTR positions matched by distance to the downstream coding sequence.
This difference remained significant even when compared to potential stop-creating positions in
5’UTR sequences adjacent to (but not within) translated uORFs (Figure 3.3b). Strikingly,
conservation at each stop-creating position within mapped translated uORFs mirrored the
strength of stop-codon contexts, with a positive correlation between the strength of the potential
stop codon introduced and the proportion of uORF genomic positions that are conserved. This
trend was not observed for non-translated 5’UTR contexts (Figure 3.3b). In all cases, the
proportion of conserved bases for each class of potential stop-creating variant was significantly
higher than those positions in all 5’UTRs, and particularly within untranslated regions of
translated-uORF containing UTRs (P<0.001, Figure 3.3b). Moreover, the proportion of highly
conserved bases at possible stop-creating positions increased in association with increasing
gene constraint, as determined by the gnomAD LOEUF score, and remained significantly higher
than non-uORF 5’UTR stop-creating positions (Figure 3.13). Together, these complementary
analyses support our initial findings that UTC mutations are under strong negative selection within
the human genome, and further strengthens the evidence that UTC mutations may functionally
disrupt protein expression.

3.6: Upstream open reading frames are not under strong selection to maintain amino
acid identity
Multiple transcriptome-wide ribosome profiling studies have proposed that some uORFs can
encode functional micropeptides with important cellular roles [106,107,121]. This has fostered
significant interest in the possibility that translated, non-canonical ORFs represent an overlooked
class of potentially functional micropeptides with biological activity independent of the
downstream protein-coding sequences [107,146]. If many uORFs encoded functional
micropeptides, the pattern of constraint against UTC mutations might also reflect selection to
53

preserve micropeptide function rather than downstream translation initiation. To address this
possibility, we asked whether uORFs broadly exhibit similar constraints against missense
variation, compared to known protein-coding regions of the genome, that could imply peptide
functionality. We compared MAPS scores for predicted missense versus synonymous mutations
in translated uORFs to those in canonical protein-coding regions of the genome (Figure 3.4). The
MAPS scores for missense mutations in uORFs were significantly lower than that of missense
mutations in canonical protein-coding regions of the genome, and not significantly higher than
MAPS scores for synonymous variants in translated uORFs (P=0.7118, Figure 3.4a-iv). These
results indicate that selection to maintain amino acid identity in uORF-encoded micropeptides is
weak compared to canonical protein-coding sequences. As an additional control, we computed
MAPS scores for predicted missense and synonymous mutations in 693, 1188, and 276
translated non-canonical ORFs (ncORFs) mapped by ribosome profiling in 3’UTRs (dORFs),
long-noncoding RNAs, and pseudogenes respectively, as these sequences are not thought to
broadly encode for functional peptides. Similar to uORFs, predicted missense variants in these
additional ncORFs were not significantly higher than predicted synonymous variants by MAPS
score (dORFs P=0.3532; lncRNAs P=0.7777, pseudogenes P=0.4523 Figure 3.4a-i-iii).
Since many translated uORFs are short, we asked whether longer uORFs might exhibit greater
selection against missense variants compared to shorter uORFs. To test this possibility, we
divided uORFs into long sequences >118 codons comprising the top 25% longest mapped
uORFs, and short uORFs <118 codons in length. MAPS scores for missense variants in long
versus short uORFs yielded no evidence of significant constraint acting on amino-acid changing
variants compared to synonymous SNVs (long uORFs P=0.178, short uORFs P=0.9628, Figure
3.4a-v).

54

Figure 3.4: ncORFs do not exhibit strong selective pressure to maintain amino acid
identity. MAPS scores for single nucleotide variants within each ncORF category separated by
predicted consequence (synonymous or missense) in each ORF. (i-iv) Allele frequencies for
predicted missense SNVs are not significantly enriched for singletons than those for predicted
synonymous SNVs. (v) MAPS scores are no different for long uORFs (> 118 codons) compared
to the rest (short). Grey, orange, and purple dashed lines represent MAPS scores for
synonymous, missense, and predicted loss-of-function (pLOF) SNVs affecting canonical protein
coding sequences in gnomAD. Error bars represent bootstrapped 90% confidence intervals.
Surprisingly, we observed that MAPS scores for both synonymous and missense variants in
translated uORFs deviated significantly from all 5’UTR variation (Figure 3.4a-iv). These
heightened MAPS scores implied that uORF variants are under increased negative selection
compared to all 5’UTR variants. The absence of similar effects for variants in dORFs, lncRNAs, or
translated pseudogenes implies that this enrichment in singletons is unique to translated uORFs.
One possibility is that synonymous variation in uORFs reflect selective pressures to maintain
translational efficiency by preserving codon optimality. Messenger RNAs that are enriched with
more optimal codons are both more stable, and more efficiently translated by ribosomes [147].
Like UTC mutations, uORF mutations introducing suboptimal codons could therefore slow
translational elongation and impede downstream translation initiation at the CDS. Indeed,
mutations introducing suboptimal codons in translated uORFs have been shown to disrupt
translation initiation at downstream coding sequences [148–150], and more generally 5’UTRs are
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under selective pressures to maintain their capacity for facilitating translation initiation at the CDS
[151,152].

Figure 3.5: Synonymous and missense variants in translated uORFs are under selective
pressure to maintain codon optimality. (a) Translated uORF variants ranked by predicted
change to codon optimality using codon stability coefficient (CSC) scores from SLAM-seq (red =
decreasing, blue = increasing) [110]. Grey dotted line denotes boundary separating optimality
increasing versus decreasing SNVs. (b) MAPS scores for SNVs separated by predicted
consequence on codon optimality shows heightened constraint against decreasing optimality
variants, while variants increasing optimality are indistinguishable from all 5’UTR variants. Error
bars represent bootstrapped 90% confidence intervals.
To test whether mutations in translated uORFs are constrained to maintain codon optimality, we
asked if MAPS scores for mutations predicted to decrease codon optimality differed from those
that increased codon optimality (Figure 3.5a). Using experimentally determined codon-stability
coefficients (CSCs) [153], we matched each uORF SNV with its predicted consequence to codon
optimality, and compared MAPS scores for optimality-increasing versus optimality-decreasing
SNVs. As expected, SNVs increasing codon optimality were indistinguishable from all 5’UTR
variants (P=0.1929, Figure 3.5b). In contrast, variants predicted to decrease codon optimality had
significantly higher MAPS scores (P<0.001), although the magnitude of this difference is
moderate compared to UTC mutations (Figure 3.3b). This effect remained significant regardless
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of whether variants were predicted to cause synonymous or missense mutations (P=0.0125 for
synonymous; P=0.009 for missense), and was notably absent for translated ORFs in 3’UTRs,
lncRNAs, and pseudogenes (Figure 3.5b, Figure 3.14). Furthermore, this pattern of increased
constraint against optimality-decreasing mutations was robust to the use of CSC scores derived
from alternative experimental approaches across several cell lines (Figure 3.15) [153]. Together,
these observations further support the hypothesis that natural selection acts to maintain the
capacity for translational initiation at downstream coding sequences by preserving translational
elongation efficiency in uORFs.

3.7: uORF start codons are conserved and under strong selective pressure
The finding of heightened selection against translation-interrupting variants in uORFs raises the
question of why translated uORFs continue to persist in a large fraction of human genes.
Evidence that uORF-CDS organization, and the strength of uORF repression is strongly
conserved across vertebrates, suggests that translation at uORFs is maintained to regulate
downstream translation initiation [122]. Moreover, variants destroying uORF start codons have
been implicated in the development of cancer [154]. To provide further genetic evidence that
translation at uORFs is maintained by selection, we asked whether allele frequencies for variants
affecting uORF start codons also exhibited strong selection to maintain their capacity for
translation initiation. Using the MAPS metric, and genome-wide phyloP scores, we evaluated
patterns of variation affecting uORF start codons. Since many translated uORFs begin with noncanonical start codons (Figure 3.6a-i), we distinguish between variants maintaining the start
context by affecting the first position of the NUG trinucleotide from those that disrupt translation
initiation by mutating the last two nucleotides in the uORF start codon (Figure 3.6a-ii). As
expected, start-maintaining variants are no more enriched for singletons in gnomAD compared to
synonymous protein coding variants. In contrast, start-disrupting mutations are enriched for
singletons at a level comparable to that of protein-coding missense and UTC mutations (Figure
3.7). The heightened pressure to maintain translational initiation at uORF start codons is similarly
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reflected in phyloP scores for uORF start-disrupting genomic positions compared to distancematched UTR controls (P < 0.001), and uORF-matched controls (P < 0.001, Figure 3.8). These
data show that translation initiation at uORFs is evolutionarily constrained in humans, and are
consistent with previous reports that uORF start codons are frequently conserved across species.
Taken together, our analyses of genetic variation in gnomAD show enrichment for rare allele
frequencies in the frequency spectra of uORF start-disrupting, stop creating, and stopstrengthening mutations. Results from our analyses indicate that these classes of variation are
under a heightened degree of negative selection, and imply that processes of translation
initiation, elongation, and termination at translated uORFs are maintained by selective pressure.

Figure 3.6: Start codon usage for uORFs mapped by ribosome profiling. (i) Distribution of
start codon usage for experimentally mapped translated uORFs, and (ii) possible consequences
of mutations affecting uORF start codons.
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Figure 3.7: MAPS scores for uORF start disrupting variants. (i) MAPS scores for startdisrupting SNVs are compared to uORF variants matched by trinucleotide mutation context. (ii)
Start-disrupting SNVs for short (< 20 codons) uORFs are under stronger negative selection
compared to start-disrupting variants for long (>= 20 codons) uORFs. Error bars represent
bootstrapped 90% confidence intervals.
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Figure 3.8: PhyloP estimates for possible start codon disrupting positions. uORFs start
disrupting positions are compared to all uORF SNVs, UTR-matched start-disrupting positions,
and uORF-matched start-disrupting positions in translated uORFs. Start-disrupting genomic
positions of short uORFs are more strongly conserved by phyloP scores compared to matched
start-disrupting positions within uORFs. Error bars represent bootstrapped 90% confidence
intervals.

3.8: uORF-disrupting variants associate genes with new disease phenotypes
The heightened MAPS score for UTC mutations suggests that they are also likely to be
functional. To explore the possibility that UTC and uORF stop-strengthening mutations might
contribute functionally to human disease susceptibility, we performed a phenome-wide
association study (PheWAS) of predicted uORF-disrupting variants using the Penn Medicine
Biobank (PMBB) - a large academic biobank with exome sequencing linked to EHR data for
10,900 individuals [155].
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Table 3.1: Significant novel associations in PheWAS of Penn Medicine BioBank
Variant

Novel associations

Replication

Gene
(SNP, uORF
effect)

Phenotype
(Phecode)

OR (95%
CI)

P value

Case
s

Contr
ols

UKB

PMBB LOF

UKBB LOF

PMVK*
(rs181302437)
UAG>UAA

250.13 (T1D ophthalmic
manifestations)

27.29
(6.88108.29)

2.58E06

23

5189

No

No

Yes
(250.13,
P = 7.27e03)

250.14 (T1D neurological
manifestations)

22.71
(5.8687.97)

6.20E06

25

5189

No

No

No

250.22 (T2D renal
manifestations)

7.79
(2.8721.17)

5.73E05

136

5189

No

No

No

300.10
(Anxiety
disorder)

0.64
(0.530.77)

4.23E06

1060

6939

No

No

No

300.00
(Anxiety
disorders)

0.69
(0.580.82)

2.00E05

1249

6939

No

No

No

NALCN
(rs139848407)
CAA>UAA

270.33
(Amyloidosis)

38.92
(7.49202.36)

1.34E05

30

7727

No

No

Yes
(270.00,
P=0.0264)

BCL2L13†
(rs140799351)
UGA>UAA

610.00 (Benign
mammary
dysplasias)

270.57
(19.693718.08)

2.80E05

55

7689

No

Insufficient
variants

Insufficient
variants

187.20
(Malignmant
neoplasm of
the testes)

331.41
(21.685065.35)

3.03E05

26

7700

Yes
(187.20, P
= 2.09e-4)

Insufficient
variants

Insufficient
variants

187.00
(Cancer of
other male
genital organs)

220.01
(15.673089.83)

6.31E05

34

7700

Yes
(187.00, P
= 3.33e-4)

Insufficient
variants

Insufficient
variants

SHMT2
(rs28365863)
UAG>UAA

527.00
(Diseases of
the salivary
glands)

6.37
(2.6015.65)

5.27E05

90

9774

Insufficient
cases

Yes (527.00,
P = 5.515e03)

Insufficient
cases

MOAP1
(rs116450723)
UAC>UAA

350.00
(Abnormal
movement)

4.99
(2.2011.33)

1.22E04

362

9414

No (variant
not present
in UKB)

No

No (variant
not present
in UKB)

VPS53
(rs35915949)
UGA>UAA
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*As of the Gencode 32 release the 5’UTR PMVK annotation (September 2019) was shortened to
exclude this uORF; however inspection of the raw ribosome profiling reads from Ji et al. [121] in
conjunction with nearby transcription start sites annotated in FANTOM5 confirm the presence of a
longer PMVK 5’UTR isoform (Figure 3.17). †The stop-strengthening variant in BCL2L13 affects a
minor transcript isoform, and is also annotated as a synonymous mutation on the primary
BCL2L13 transcript.

Using exome sequencing from the PMBB, we identified heterozygous and homozygous
individuals carrying UTC and stop-strengthening mutations. For the former class, we focused on
variants introducing UAA stop codons, as the heightened MAPS score for such variants implied
these mutations would be most deleterious. Filtering for variants with at least 5 heterozygous
carriers with high-quality genotype, we identified 10 variants matching the above criteria (6 stopstrengthening mutations, 4 UAA-UTC mutations). For each of these mutations we performed a
single-variant PheWAS across 800 EHR phenotypes. Of those 10 candidates, 6 passed an FDR
threshold of 0.1 (P<1.25e-4) used in previous PheWAS studies [156,157], including 5/6 of the
stop-strengthening variants and 1/4 of the UAA UTCs. Even more strikingly, two of these six
variants passed a highly conservative Bonferroni correction (P<6.25e-6), both being uORF stopstrengthening variants. The stop-strengthening variant in PMVK was associated with increased
risk of Type 1 diabetes while the stop-strengthening variant in VPS53 was associated with a
protective effect against anxiety disorders (Figure 3.9, Figure 3.16, Table 1, Table 3.4). Notably,
of the identified phenotype-associated variants, only VPS53 is annotated as a cis-eQTL in the
latest GTEx release (version 8).
To replicate associations from our exploratory analysis in the PMBB, we performed additional
single-variant association analyses for each of the 6 significant variant-phenotype associations in
the UK Biobank (UKB). Direct replication using the original significant 4- or 5-digit ICD-9 code
from the PMBB was tested for each variant-phenotype association. Where there were insufficient
case numbers in the UKB, we used the broader 3-digit ICD-9 code. Out of six novel associations
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reaching FDR < 0.1, one (rs140799351) showed P < 0.05 in the UKB at the 5-digit ICD code
level, reaching study-wide significance (Table 3.1, Table 3.5). For the remaining putative novel
associations, the VPS53 uORF stop-strengthening variant did not replicate, although the direction
of effect is consistent with results from the PMBB. Finally variants in SHMT2 could not be
replicated because there were fewer than 20 cases in the UKB cohort, and MOAP1 could not be
replicated because this variant was absent from the UKB.

Figure 3.9: Phenome-wide association study (PheWAS) of predicted stop-strengthening
variant in a translated uORF in PMVK. PheWAS plot of translated uORF stop-strengthening
variant in the 5’UTR of PMVK (N = 65 carriers) in the Penn Medicine BioBank. ICD-9 and ICD-10
Phecodes are organized and plotted by category on the X-axis. The solid red line represents the
threshold for Bonferroni-adjusted significance (P=6.25e-6) and the red dashed line represents the
FDR threshold (P=1.25e-4). The direction of each arrowhead corresponds to increased risk (up)
or decreased risk (down).
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3.9: Disease-associated uORF variants change protein expression
To elucidate the possible biological consequences of UTC and stop-strengthening mutations, we
selected three PheWAS association signals in the discovery analysis for functional assessment.
To determine if these variants could affect protein expression, we measured the expression of a
set of dual-luciferase reporters in HEK293T cells for PMVK, VPS53, and the BCL2L13 uORF
variants. We compared the expression of the wild-type 5’UTR sequence for PMVK, VPS53, and
BCL2L13 cloned upstream of a Firefly Luciferase ORF to two variant sequences - one with the
predicted uORF start codon removed, and a second sequence with the PheWAS-significant stopstrengthening mutation inserted. For VPS53, we also tested the effect of a mutation changing a
tryptophan UGG codon to a UAG UTC (Figure 3.10b). Across all constructs, we observed a
significant reduction in expression of the downstream ORF when the PheWAS-significant stopstrengthening mutation was introduced (Figure 3.10). Introducing a new UTC in the 5’UTR of
VPS53 also significantly reduced reporter protein expression relative to the wild-type sequence.
Similar results were obtained from assays performed in HeLa cells (Figure 3.22).
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Figure 3.10: Reporter gene assays for translated uORF stop-introducing and stopstrengthening variants. Dual-luciferase reporter assay quantifies relative expression for uORFs
with UTC and stop-strengthening mutations associated with EHR phenotypes by PheWAS.
Experimental 5’UTRs for (a) PMVK, (b) VPS53, and (c) BCL2L13 for uORF KO, stopstrengthened, or stop-introduced variants are shown. Bars represent co-transfected Firefly to
Renilla Luciferase luminescence ratios normalized to associated wild-type 5’UTRs in HEK293T
cells measured 48 hours post-transfection. Significant P-values from one-sample T-test for each
condition denoted by * (>0.05), ** (>0.01), and *** (>>0.001). Error bars represent mean + S.E.M.
of at least 3 independent experiments.
In all the tested constructs, UTC and stop-strengthening mutations decreased relative Firefly
expression. These data are consistent with the hypothesis that UTC or stop-strengthening
mutations are under negative selection because they decrease the probability of translation
initiation at downstream coding sequences. These results are congruous with our genetic
analysis, and imply that UTC and stop-strengthening mutations represent a new class of
functional variation in 5’UTRs capable of causing loss-of-function of downstream coding genes.

3.10: Replication of novel associations by loss-of-function gene-burden studies
Results from reporter-gene experiments showed that UTC and stop-strengthening mutations
could decrease expression of the downstream protein for PMVK, VPS53, and BCL2L13. Our
65

findings implied that uORF UTC and stop-strengthening mutations cause phenotypic
consequences through potential loss-of-function of the downstream protein-coding gene. To
further validate this hypothesis, we performed a gene burden test by aggregating rare loss-offunction protein-coding variants in the PMBB and UKB for each significant uORF-PheWAS
association. These studies could confirm that predicted loss-of-function in the protein coding
sequence of the uORF-regulated gene causes the same phenotype as the uORF UTC or stopstrengthening mutations. Indeed, similar loss-of-function gene burden approaches using rare
protein-coding variants have successfully been applied to identify both known and new genedisease associations in the PMBB and UKB [155,158].
Of six PheWAS-significant associations uncovered in our discovery analysis (FDR<0.1), two
associations were replicated by an independent loss-of-function gene burden test in either the
UKB or PMBB. The associations between PMVK and diabetes, and SHMT2 and diseases of the
salivary gland, were replicated in the UKB and PMBB respectively (PMVK P=0.00727, SHMT2
P=0.005515, Table 1, Table 3.5). Although no significant LOF-burden association for PMVK was
replicated in the PMBB, predicted loss-of-function of PMVK was nominally associated with
impaired fasting glucose (P=0.0235). A second uORF-disease association was replicated for
NALCN and the parent 3-digit parent PheCode of disorders of plasma protein metabolism in the
UKB (P=0.0264). Gene-disease associations for BCL2L13 could not be replicated in either the
PMBB or UKB due to lack of carriers for predicted loss-of-function variants. Ultimately this
analysis confirmed that loss-of-function gene burden tests using protein-coding variants are
associated with the same phenotype for two uORF stop-strengthening mutations. This evidence
of allelic heterogeneity for these phenotypes further strengthens the likelihood that uORF stopstrengthening variants can cause loss-of-function of downstream protein-coding genes.
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3.11: Summary and future directions
By combining large databases of human genetic variation with ribosome profiling, we identified
two new categories of mutations in 5’UTRs capable of causing loss-of-function in downstream
coding genes. These mutations either introduce upstream termination codons in uORFs or
strengthen uORF stop sites. Given that ~50% of human protein-coding genes are estimated to be
under translational control by uORFs, these findings provide a novel framework for interpreting
the functional significance of 5’UTR variation for a large fraction of human genes.
Using these mutations, we additionally identified new gene-disease associations in the PMBB
and replicated one of these associations in independent single-variant association tests in the
UKB. Two associations involving stop-strengthening variants in PMVK and SHMT2 and one
involving a UTC in NALCN were also replicated using protein-coding mutations in loss-of-function
gene burden tests. These results provide independent validation of uORF variant-phenotype
associations uncovered through the PMBB discovery analysis and demonstrate that uORF stopstrengthening and UTC mutations associate with the same phenotype as predicted loss-offunction coding mutations in downstream coding sequences. In support of these conclusions, we
have shown that introducing UTCs and stop-strengthening mutations in translated uORFs
decreases protein expression of downstream genes in reporter assays. These findings establish
that uORF UTC and stop-strengthening mutations can have functional consequences on protein
expression and are associated with disease in humans. If we assume that pathogenic UTC or
stop-strengthening mutations are under similar selective pressures as pathogenic loss-of-function
variants in protein-coding regions of the genome, we estimate that approximately 24% (90% CI
21-28%) of uORF-containing genes may be affected by UTC and stop-strengthening mutations
with severe pathogenic consequences (3.13: Suppl. Note). Moreover, if we assume that
missense mutations in functional uORF micropeptides are similarly enriched in singletons as in
protein-coding regions of the genome, we estimate that ~5-15% of translated uORFs are under
constraint for amino acid function (3.13: Suppl. Note). This latter estimate is consistent with
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recent CRISPR screens reporting a statistically significant decrease in growth phenotypes for
~14% (157/1098) of uORF-specific knockouts across two cell lines when the CDS was preserved
[107]. Finally, of the 4392 genes with translated uORFs used for this analysis, 1121 (26%) are
also annotated as having pathogenic coding sequence variants in ClinVar, suggesting that UTC
and stop-strengthening mutations in these genes may have additional utility for the diagnosis of
rare disease.
Our results suggest uORF translation has broad roles in regulating CDS translation. Translation
initiation is rate-limiting for protein production and selection against mutations disrupting
translation elongation (UTCs) or termination at uORFs (stop-strengthening variants) may reflect
the importance of preserving translation initiation efficiency at the CDS. This suggested mode of
regulation is in-line with observations that cis-regulatory relationships between uORFs and
downstream coding sequences are frequently conserved across vertebrates while features
conferring strong uORF repression are less maintained [122,124]. For stop-strengthening
variants, the increased translation termination efficiency could accelerate ribosomal release from
the mRNA transcript, thus decreasing downstream CDS translation. This mechanism is
consistent with previous data in human cell lines showing that decreased translation termination
efficiency by global knockdown of eRF3A increases translation of genes under uORF-repression
[159, 160]. For UTC mutations, the introduction of stop codons in the uORF may lead to either
ribosome stalling and subsequent collisions that further repress CDS expression [161,162]. This
early translation termination in uORFs might also facilitate greater rates of premature ribosome
release from the mRNA transcript, or can lead to nonsense mediated decay (NMD). While a
handful of translated uORFs that activate NMD have been described in the literature [163–165],
whether uORF-activated NMD broadly regulates protein expression remains an open question.
Indeed, depletion of UPF1, a central component of the canonical NMD pathway, produced only
minimal changes in uORF-containing mRNAs abundance in human cell lines [159].
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The capacity for translated uORFs to produce functional micropeptides independent of regulating
CDS expression remains an area of active investigation. In canonical protein-coding regions of
the genome, amino acid substitutions in critical protein domains can be highly deleterious for
cellular functioning and fitness. Previous studies have found that uORF-encoded peptides show
evidence of amino acid conservation using statistical tests relying on a null hypothesis of neutral
selection [121]. It is unclear if the conclusions drawn from these approaches account for the
possibility that codon-optimality constrains variation within uORFs rather than amino acid identity.
In contrast, we do not observe similar constraints on missense mutations in translated uORFs,
suggesting that amino acid substitutions within most uORF-encoded micropeptides are welltolerated in humans. This was also the case for other non-canonical translated ORFs, including
3’UTR ORFs, pseudogenes, and lncRNAs, that are not thought to widely encode for functional
micropeptides. Although a handful of functional micropeptides have been identified previously,
our analysis implies that most ncORFs do not produce peptide products whose function depends
on their amino acid composition. It is also important to note that ribosomes are among the most
abundant proteins within cells, occupying approximately 5% of the entire intracellular volume
[166]. As improvements in ribosome profiling facilitate deeper characterization of the translatome,
observations of widespread translation in non-canonical ORFs should be interpreted cautiously in
light of potential functionality.
Interestingly, bi-allelic loss-of-function mutations in SHMT2 have recently been described in a
novel brain and heart developmental syndrome involving spastic paraparesis and ataxias [167].
Indeed, in addition to the phenome-wide significant association with diseases of the salivary
gland uncovered in our study, the SHMT2 uORF stop-strengthening variant was nominally
associated with several Phecodes related to cardiac and movement disorders in the PMBB
(Table 3.7), including Congenital anomalies of the great vessels (ICD 747.13, P = 0.0117),
Abnormal involuntary movements (350.1, P = 0.0238), Abnormality of gait (350.2, P = 0.02575),
Mobitz II AV block (426.22, P = 0.03432), and Arrhythmia (cardiac) NOS (427.5, P = 0.04977).
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These additional nominal associations suggest that SHMT2 uORF variants may be capable of
contributing to similar phenotypic consequences as described in loss-of-function mutation
carriers, however further studies are needed to investigate this possibility. The novel association
between stop-strengthening and pLOF variants in PMVK with diabetes further strengthens
existing genetic and epidemiological evidence linking the mevalonate pathway to diabetes. PMVK
encodes for phosphomevalonate kinase, an enzyme in the mevalonate pathway catalyzing the
conversion of mevalonate-5-phosphate to mevalonate-pyrophosphate downstream of HMG-CoA
reductase. Multiple randomized clinical trials have shown that inhibiting HMG-CoA reductase with
statins increases the risk of developing new-onset type 2 diabetes in a dose-dependent manner,
although the mechanism driving this association has remained elusive [168–170]. Moreover,
genetic variants in and near the HMGCR gene that are associated with lowered LDL cholesterol
levels have been similarly shown to confer an increased risk of developing diabetes [171,172],
suggesting that decreased HMGCR activity contributes to diabetes pathogenesis. Our data is the
first to establish a putative link between PMVK and diabetes. Given the shared involvement of
PMVK and HMGCR genes in the mevalonate pathway, it is possible that variants in both these
genes confer an increased risk of diabetes through a similar mechanism, however additional
studies will be needed to further elucidate the precise relationship between PMVK and diabetes.
A limitation of our analysis is that we cannot directly assess the impact of additional factors on
uORF-mediated translational regulation. As an example, a pathogenic UTC mutation in the U2HR
gene has previously been reported to confer gain-of-function in Marie Unna hereditary
hypotrichosis [173]. However, missense variants in this uORF also confer gain-of-function effects,
suggesting that these mutations contribute to pathology through disrupting a functional
micropeptide. Indeed, previous studies have shown that a multitude of factors may impact uORF
regulatory function and dissecting these effects remains a challenge for future studies.
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Finally, we note that being a hospital-based biobank, participants in the PMBB are generally less
healthy than the general population. As phenotypes within broader disease Phecode families are
often highly correlated, we sought to replicate associations uncovered in the discovery analysis
by first testing for a specific hypothesis-driven phenotype association in addition to related
phenotypes in the corresponding Phecode families. We recognize that controlling for Type 1 error
in this framework remains challenging. However, to remedy this we sought additional confidence
by further replicating significant uORF-variant associations through loss-of-function gene-burden
analyses. Moreover, the relative enrichment in diseased individuals in the PMBB may account for
why few associations discovered in our analysis of the PMBB are replicated in the UKB which
contains a healthy volunteer selection bias [174]. Indeed, we were unable to test for an
association for two of the six PMBB associations due to an inadequate number of individuals
having the phenotype in UKB. As hospital-based biobanks become more prevalent these
unreplicated associations should be revisited and confirmed.
Understanding and interpreting the impact of noncoding genetic variation is a fundamental
challenge in biology. Many mutations affecting uORFs are known to cause disease [175–178],
but until now, most studies have focused on mutations which abolish start codons, stop codons of
existing uORFs, or those that create new inhibitory uORFs. By examining patterns of genetic
variation within translated uORFs, we have uncovered two new categories of variation affecting
5’UTRs that may lead to loss-of-function in associated genes. We have used these variants to
identify new gene-disease associations, and provide evidence for their ability to impact
downstream gene expression. Our approach demonstrates the power of integrating populationscale databases of human genetic variation with cellular-scale -omics data to identify new
patterns of how variation impacts regulatory elements. Taken together, our data broadens the
scope of functional translational regulation by uORFs in the transcriptome and establishes new
approaches for interpreting functional genetic variation in 5’UTRs.

71

3.12: Supplementary Figures and Tables for Disrupting upstream translation in mRNAs
is associated with human disease

Figure 3.11: Distribution of protein coding ORFs, uORFs, and other non-canonical ORFs
mapped by ribosome profiling from Ji et. al paper [121]. dORFs represent ORFs mapped in
3’UTRs, lncRNAs represent ORFs mapped in long-noncoding RNAs, and pseudogenes represent
translated pseudogenes respectively.
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Figure 3.12: MAPS scores for uORF UTC-creating and stop-strengthening variants
compared to non UTC-creating or stop-strengthening uORF variants matched by
trinucleotide mutation context. Error bars represent bootstrapped 90% confidence intervals.

Figure 3.13: PhyloP scores for possible UTC-creating positions and gnomAD proteincoding constraint. PhyloP scores in translated uORFs (red) compared to 5’UTR sequences
(black) across all sextiles of gene constraint as determined by gnomAD LOEUF scores (1 being
least constrained, 6 being most constrained).
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Figure 3.14: Optimality changing MAPS scores for SNVs in dORFs (3’UTRs), pseudogenes,
and long-noncoding RNAs (lncRNAs). Error bars represent bootstrapped 90% confidence
intervals.
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Figure 3.15: MAPS score for optimality changing variants using different optimality scores.
MAPS dependence on whether a SNV increases or decreases codon optimality in uORFs is
robust to changing CSC-scores used to calculate codon optimality across 293 cell lines using the
orfome approach, and from retinal pigment epithelium cells with CSC-scores calculated using
endogenous mRNAs [153].
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Figure 3.16: PheWAS plot of VPS53 stop-strengthening variant. Red solid line indicates
Bonferroni significance threshold (P=6.25e-05). Red dashed line represents the FDR < 0.1
threshold.
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Figure 3.17: Change in PMVK 5’UTR annotation as of September 2019 Gencode 32 release.
The longer 5’UTR isoform for PMVK is supported by transcription start-site mapping from
FANTOM5, and by the remapped ribosome-profiling reads (top, black) from GSE65885.

Figure 3.18: PheWAS plot of BCL2L13 stop-strengthening variant. Red solid line indicates
Bonferroni significance threshold (P=6.25e-05). Red dashed line represents the FDR < 0.1
threshold.
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Figure 3.19: PheWAS plot of NALCN UAA UTC variant. Red solid line indicates Bonferroni
significance threshold (P=6.25e-05). Red dashed line represents the FDR < 0.1 threshold.
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Figure 3.20: PheWAS plot of SHMT2 stop-strengthening variant. Red solid line indicates
Bonferroni significance threshold (P=6.25e-05). Red dashed line represents the FDR < 0.1
threshold.
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Figure 3.21: PheWAS plot of MOAP1 UAA UTC variant. Red solid line indicates Bonferroni
significance threshold (P=6.25e-05). Red dashed line represents the FDR < 0.1 threshold.

80

Figure 3.22: Luciferase experiments for PMVK and VPS53 plasmid Constructs showing
similar direction of effect for UTC and stop-strengthening variants using HeLa cells for
transfection.
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Table 3.2: uORF UTC / Stop-strengthening MAPS analysis with all CDS-overlapping
variants removed.

Table 3.3: Relative frequencies of TGA, TAG, and UAA trinucleotides across different
5’UTR sequence contexts

Table 3.4: Minor allele frequencies for all PheWAS-significant variants tested in discovery
and replication analyses
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Table 3.5: PheWAS replication analyses phenotypes tested

Table 3.6: 5’UTR Fragments used in expression constructs
Gene
(Transcript)

Mutatio
n

Sequence

PMVK
(ENST0000
0368467)

WT

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGAGAAGGTTCTGGGCGGGGCTGGACTGTT
CTAAGTGAGTTCGGGTGGGGGAGCTTCACGAGGGGAGG
CTGCTCTGTGAAGGAACCGCCTTTCTCTCCGCGTGTCTCA
CCCTTTTCTCCCCATATCTGTTTGGACATGAGCTGAGGGC
ACGGTCGCGGGCGGTCAGCCCTGTTCGCAGCTACGGCG
AGGAGGGGCGCGATTGTTCCTTGTTGCCGCTCCGCTTAG
TGGCCGCGTCCATTCCGCGCGGTGTCCCGATTTTAGGGG
TAGGGAGAAGTGTCAGCTTCAGGCATCGCGAGGCGTGGC
GGCCCCATGGAAGATGCCAAAAACATTAAGAAGGGCCCA
GCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAG
CAGCTGCACAAAGCCATGA

PMVK
(ENST0000
0368467)

KO

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGAGAAGGTTCTGGGCGGGGCTGGACTGTT
CTAAGTGAGTTCGGGTGGGGGAGCTTCACGAGGGGAGG
CTGCTCTGTGAAGGAACCGCCTTTCTCTCCGCGTGTCTCA
CCCTTTTCTCCCCATATCTGTTTGGACATGAGCTGAGGGC
ACGGTCGCGGGCGGTCAGCCCTGTTCGCAGCTACGGCG
AGGAGGGGCGCGATTGTTCCTTGTTGCCGCTCCGCTTAG
TGGCCGCGTCCATTCCGCGCGTTTTCCCGATTTTAGGGGT
AGGGAGAAGTGTCAGCTTCAGGCATCGCGAGGCGTGGCG
GCCCCATGGAAGATGCCAAAAACATTAAGAAGGGCCCAG
CGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAGC
AGCTGCACAAAGCCATGA

PMVK
(ENST0000
0368467)

TAG>T
AA

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGAGAAGGTTCTGGGCGGGGCTGGACTGTT
CTAAGTGAGTTCGGGTGGGGGAGCTTCACGAGGGGAGG
CTGCTCTGTGAAGGAACCGCCTTTCTCTCCGCGTGTCTCA
CCCTTTTCTCCCCATATCTGTTTGGACATGAGCTGAGGGC
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ACGGTCGCGGGCGGTCAGCCCTGTTCGCAGCTACGGCG
AGGAGGGGCGCGATTGTTCCTTGTTGCCGCTCCGCTTAG
TGGCCGCGTCCATTCCGCGCGGTGTCCCGATTTTAAGGG
TAGGGAGAAGTGTCAGCTTCAGGCATCGCGAGGCGTGGC
GGCCCCATGGAAGATGCCAAAAACATTAAGAAGGGCCCA
GCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCGAG
CAGCTGCACAAAGCCATGA
VPS53
(ENST0000
0437048)

WT

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGACTGGGGCCTGGGTGGCGGCTGGAGGC
CTGAGTTGGGCTCGCGGCGGGGGTCGGCAGGGGGCCGG
GTGGCGGAATGGAAGATGCCAAAAACATTAAGAAGGGCC
CAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCG
AGCAGCTGCACAAAGCCATGA

VPS53
(ENST0000
0437048)

KO

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGACAGGGGCCTGGGTGGCGGCTGGAGGC
CTGAGTTGGGCTCGCGGCGGGGGTCGGCAGGGGGCCGG
GTGGCGGAATGGAAGATGCCAAAAACATTAAGAAGGGCC
CAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCG
AGCAGCTGCACAAAGCCATGA

VPS53
(ENST0000
0437048)

TGA>T
AA

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGACTGGGGCCTGGGTGGCGGCTGGAGGC
CTAAGTTGGGCTCGCGGCGGGGGTCGGCAGGGGGCCGG
GTGGCGGAATGGAAGATGCCAAAAACATTAAGAAGGGCC
CAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCG
AGCAGCTGCACAAAGCCATGA

VPS53
(ENST0000
0437048)

TGG>T
AG

TATAGGGAGACCCAAGCTGGCTAGTTAAGCTTAGATCTTG
ATATCCTCGAGACTGGGGCCTGGGTAGCGGCTGGAGGCC
TGAGTTGGGCTCGCGGCGGGGGTCGGCAGGGGGCCGG
GTGGCGGAATGGAAGATGCCAAAAACATTAAGAAGGGCC
CAGCGCCATTCTACCCACTCGAAGACGGGACCGCCGGCG
AGCAGCTGCACAAAGCCATGA

BCL2L13
(ENST0000
0543133)

WT

TCGGAGCACTCACCGCCGCTGGGGGACCCTGTCGGAAG
CAACTGCCGCCGCCGCCTCTTTCATCTCTTCTGGGGCAG
GGGCCAGGGCCAGGTTTTACACATCCATAAGTAGACCTTT
TTGGAGCCTCACCAGCCAATTCAATGGCGTCCTCTTCTAC
TGTGCCT
CTGGGATTTCACTATGAAACAAAGTATGTTGTTCTCAGCTA
CTTGGGACTCCTCTCTCAAGAGAAGCTGCAAGAGCAACAT
CTTTCCTCACCCCAAGGGGTTCAACTAGATATAGCTTCAC
AATCTCTGGATCAAGAAATTTTATTAAAAGTTAAAACTGAA
ATTGAAGAAGAGCTAAAATCTCTGGACAAAGAAATTTCTGA
AGGCCAGTGACATATCAGGCATTTCGGGAATGTACACTGG
AGACCACAGTTCATGCCAGCGGCTGGAATAAGATTTTGGT
GCCTCTGGTTTTGCTACGACAA

BCL2L13
(ENST0000
0543133)

ATG>A
TA

TCGGAGCACTCACCGCCGCTGGGGGACCCTGTCGGAAG
CAACTGCCGCCGCCGCCTCTTTCATCTCTTCTGGGGCAG
GGGCCAGGGCCAGGTTTTACACATCCATAAGTAGACCTTT
TTGGAGCCTCACCAGCCAATTCAATAGCGTCCTCTTCTAC
TGTGCCT
CTGGGATTTCACTATGAAACAAAGTATGTTGTTCTCAGCTA
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CTTGGGACTCCTCTCTCAAGAGAAGCTGCAAGAGCAACAT
CTTTCCTCACCCCAAGGGGTTCAACTAGATATAGCTTCAC
AATCTCTGGATCAAGAAATTTTATTAAAAGTTAAAACTGAA
ATTGAAGAAGAGCTAAAATCTCTGGACAAAGAAATTTCTGA
AGGCCAGTGACATATCAGGCATTTCGGGAATGTACACTGG
AGACCACAGTTCATGCCAGCGGCTGGAATAAGATTTTGGT
GCCTCTGGTTTTGCTACGACAA
BCL2L13
(ENST0000
0543133)

TGA>T
AA

TCGGAGCACTCACCGCCGCTGGGGGACCCTGTCGGAAG
CAACTGCCGCCGCCGCCTCTTTCATCTCTTCTGGGGCAG
GGGCCAGGGCCAGGTTTTACACATCCATAAGTAGACCTTT
TTGGAGCCTCACCAGCCAATTCAATGGCGTCCTCTTCTAC
TGTGCCT
CTGGGATTTCACTATGAAACAAAGTATGTTGTTCTCAGCTA
CTTGGGACTCCTCTCTCAAGAGAAGCTGCAAGAGCAACAT
CTTTCCTCACCCCAAGGGGTTCAACTAGATATAGCTTCAC
AATCTCTGGATCAAGAAATTTTATTAAAAGTTAAAACTGAA
ATTGAAGAAGAGCTAAAATCTCTGGACAAAGAAATTTCTGA
AGGCCAGTAACATATCAGGCATTTCGGGAATGTACACTGG
AGACCACAGTTCATGCCAGCGGCTGGAATAAGATTTTGGT
GCCTCTGGTTTTGCTACGACAA

Table 3.7: Nominal cardiac and movement disorder associations with SHMT2 stopstrengthening variant uncovered through PheWAS in Penn Medicine Biobank.
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3.13: Supplementary Note: Estimating the proportion of uORFs that may cause
pathogenic loss-of-function equivalent consequences in ClinVar disease genes

We assume that MAPS score for UTC and stop-strengthening variants in uORFs represent the
combination of variants from uORFs where loss-of-function is well-tolerated, and those from
uORFs where loss-of-function is not tolerated (has severe impact on fitness). In other words, the
MAPS score is a mixture of variants that are not under selective pressure, and variants that are
under comparable selective pressure to predicted loss-of-function variants in protein-coding
regions of known disease-associated genes.
Under this assumption we design a simulation study to model the association between the
proportion of pathogenic uORFs and MAPS scores for all uORF-disrupting (UTC and stopstrengthening) variants using variants from protein-coding sequences. We calculate a distribution
of MAPS scores for each simulated proportion of uORFs capable of harboring pathogenic loss-offunction variants as described in Figure 3.23.
Specifically the approach is to:
1. Randomly select ~4000 genes (approx. number of genes with uORFs) from genes in
ClinVar with annotated pathogenic consequences
2. Partition these genes to a sub-fraction of “TRUE LOF” (10%, 20%, 30%, ...) and a subfraction of “FALSE LOF”. The “TRUE LOF” genes will be contributing protein-coding LOF
variants to the MAPS score in gnomAD
3. “FALSE LOF” genes will be contributing synonymous variants annotated in gnomAD
4. Calculate MAPS score for this mixed set of TRUE LOF and synonymous variants
5. Repeat 10,000 times to build confidence intervals for each proportion of “TRUE LOF”
genes
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Figure 3.23: Sampling procedure to generate MAPS scores to model the proportion of
uORFs where UTC or stop-strengthening variants are capable of having pathogenic
consequences.
We can repeat this procedure for several fractions of “”TRUE” pathogenic genes (10-80% in
increments of 5%) and determine the range of possible MAPS scores given a particular
proportion of genes contributing true pLOF variants. Since the baseline estimate for uORF
variants is higher than that for synonymous coding variants, we adjust these MAPS scores by
adding the baseline estimate for uORF variants to all simulated MAPS scores. We then plot the
relationship between fraction of TRUE LOF genes and MAPS scores (Figure 3.24):
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Figure 3.24: Relationship between the fraction of true LOF variants in ClinVar pathogenic
genes and MAPS scores adjusted for uORF-synonymous variants baseline. Black line
represents MAPS scores for UTC and stop-strengthening variants combined in all uORFs.
Orange points represent the mean of MAPS scores over 10,000 bootstraps. Orange band
represents 90% confidence interval of 10,000 bootstraps MAPS scores at each simulated
proportion of genes contributing true pLOF variants.

We fit a simple regression model to these simulated MAPS scores as a function of the proportion
of genes contributing LOF variants, and use the fitted model to determine the proportion of LOF
features corresponding to the MAPS score for uORF-UTC and stop-strengthening variants. This
corresponds to the proportion of uORFs contributing UTC or stop-strengthening variants with
loss-of-function consequences capable of causing pathogenicity in humans. Solving this linear
equation gives an estimate of the proportion of uORFs where UTC or stop-strengthening variants
have comparable consequences as LOF protein coding variants in ClinVar pathogenic genes.
This gives us the estimate of 24.15354%. We fit separate lines to the 5% and 95% bootstrapped
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MAPS estimates at each proportion to determine the 90% confidence interval for this estimate
(21.35285 - 27.33626).
To derive an estimate of the proportion of uORFs under similar constraint to maintain amino acid
identity as protein-coding regions of the genome, we repeat the above procedure substituting
missense variants in all protein coding genes for pLOF variants in ClinVar disease-associated
genes. This procedure gives us an estimate of 9.916032% (5.216744 - 14.69604).

Figure 3.25: Relationship between the fraction of true missense variants in all proteincoding genes and MAPS scores adjusted for uORF-synonymous variants baseline. Black
line represents MAPS scores for predicted missense variants for all uORFs. Red points represent
the mean of MAPS scores over 10,000 bootstraps. Red lines above and below points represent a
simple regression line fitted to the 90% confidence interval of 10,000 bootstrap MAPS scores at
each point.
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CHAPTER 4: TRANSLATING REGULATORY INSIGHTS INTO THERAPIES

4.1: G-quadruplexes and upstream open reading frames in UTRs
Much of the human genome is noncoding, but knowledge of how and when genetic variation can
impact biology and disease has been primarily limited to coding sequences. Interpreting genetic
variation in noncoding DNA remains challenging because the universe of functional noncoding
elements in the human genome remains incompletely mapped and because the potential impact
of variants affecting known noncoding regulatory elements is difficult to predict. Here, we have
adopted an integrated omics approach towards addressing these dual challenges: first, by
examining the genetic and genomic evidence that putative G-quadruplex forming sequences in
UTRs of mRNAs are functional, and second by elucidating new patterns of functional variation
affecting translated upstream open reading frames. For putative G-quadruplex forming
sequences in UTRs, we have shown that central guanines in the canonical G-quadruplex motif
are significantly depleted of genetic variation in concordance with their importance for facilitating
stable secondary structure formation. We further find that these sequences are enriched for ciseQTLs annotated in GTEx, and overrepresented among RNA-protein binding interactions
mapped by ENCODE. Taken together, this evidence suggests that UTR G-quadruplexes are
functional noncoding elements in UTRs.
Although these studies imply that G4 forming sequences in UTRs are constrained by selection,
dissecting the precise functional importance of these sequences will be an important step to
understand their roles more clearly in gene regulation. Our finding that both 5’ and 3’UTR G4
sequences are enriched for cis-eQTLs implies that these sequences are broadly capable of
influencing mRNA abundance. In particular, the enrichment for cis-eQTLs in 3’UTR protein
suggests that G4s in 3’UTRs are involved in mediating mRNA stability [32], and that this is
accomplished by facilitating RNA-protein binding interactions. More generally, the observed
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enrichment for RNA protein binding interactions over both 5’ and 3’ UTR G4s implies that the
capacity for these secondary structures to bind proteins is central to their functionality.
Whether some subsets of G4 binding proteins bind differentially to folded versus unfolded G4
secondary structures remains an interesting question for further investigation. Indeed,
subsequent studies have replicated our findings that helicase RNA-binding proteins including
DDX6 tend to bind G-rich sequences capable of forming G4 structures [179], suggesting that
dynamic folding and unfolding UTR G4s plays a role in regulation. G4 folding could possibly mask
other regulatory protein binding sites within mRNAs, or create a new substrate for protein binding,
depending on cell state. Our finding that many UTR sequences with potential G4 structures tend
to be overrepresented among genes involved in cellular stress response pathways further implies
that differential G4 binding interactions may be involved in post-transcriptional responses to
cellular stress. Future targeted functional studies should explore this possibility further.
We have additionally examined patterns of selective pressure in non-canonical open reading
frames mapped through ribosome profiling experiments. Our analysis of allele frequencies in
gnomAD identified uORF stop-introducing and stop-strengthening variants as categories of
variation in the 5’UTR that exhibit a strong signature of negative selection, comparable to that of
missense mutations in protein-coding regions of the genome. We further demonstrate that certain
uORF stop-strengthening and stop-introducing variants associated with human disease
phenotypes in two EHR-based biobanks can decrease downstream protein expression in reporter
gene assays. Together, these data demonstrate that variants introducing new stop codons or
strengthening existing stop codons in uORFs can impact protein expression and imply that they
may contribute to human disease.
Previous studies of translational regulation by uORFs have revealed that several additional
factors, including the strength of a uORF start codon [180], intercistronic distance between the
uORF stop codon and downstream coding gene [181,182], and potential secondary structures in
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the 5’UTR can impact translational regulation by uORFs [183,184]. Although these factors were
not addressed in the current study, they are likely to influence the ability for uORF stopintroducing or stop-strengthening variants to decrease downstream protein expression. Notably,
mutagenesis studies have reported that shortening repressive uORFs significantly may result in
increased expression of downstream proteins [181]. This raises the possibility that some uORF
stop-introducing variants can confer gain-of-function rather than loss-of-function depending on the
length of the uORF they interrupt, the specific uORF that is affected, and the amount by which the
uORF is shortened. In the scanning model of translation initiation, uORF-mediated translational
repression occurs by preventing ribosomes from reacquiring the necessary translation initiation
factors in time to begin translation at the downstream CDS. Thus, uORF stop-introducing variants
may sufficiently lengthen the intercistronic distance between uORF and CDS to release
downstream coding sequences from uORF-mediated translational repression. Further
characterizing the precise relationship between intercistronic distance and uORF repressiveness
will help improve our ability to accurately predict when uORF stop-introducing variants can
increase protein expression.
The observed allele frequencies of variants affecting translated uORFs also suggests that these
regulatory elements largely act at the level of translation rather than through encoding functional
micropeptides. In support of this interpretation, we do not observe widespread evidence that
amino acid encoding is constrained in most non-canonical ORFs, but we do observe that uORF
translation initiation in 5’UTRs is maintained by selection. While there has been growing interest
in the possibility functional micropeptides are widely encoded in ncORFs throughout the genome,
the absence of significant selection to maintain amino acid encoding in ncORFs more broadly
suggests that the functionality of micropeptides is either not associated with their amino acid
encoding, or that perhaps that the fraction of functional micropeptides is much smaller than
implied through ribosome profiling studies. Indeed, as translation in 5’UTRs has long been
observed to have regulatory functions, it is possible that widespread translation in ncORFs may
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also have regulatory rather than peptide-encoding roles in biology. Nevertheless, it remains
possible that patterns of selection in ncORF encoded micropeptides do not reflect similar
selective forces as those acting in canonical protein coding regions of the genome. In this
scenario the function of ncORF micropeptides may alternatively depend on their length, or
perhaps the presence of a few key amino acids in their sequence.

4.2: From regulation to therapy
Together, our studies help expand the understanding of regulatory elements in UTRs, and the
interpretation of genetic variation in 5’ and 3’ UTRs – core components of all protein-coding
messenger RNAs. As databases of human genetic variation grow larger, so too will the resolution
by which we can observe and understand patterns of functional genetic variation in noncoding
DNA. Further work establishing detailed maps of functional noncoding RNA regulatory elements
will help inform the future development of new medicines which manipulate these regulatory
elements for therapy. Indeed, drugging RNAs has received growing interest as a therapeutic
mechanism in recent years [185]. The molecular tools of RNA manipulation – including small
interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) – have existed for decades,
however strategies for modulating protein activity or direct genome editing have traditionally
received greater attention for therapeutic development. Compared to small molecules,
oligonucleotides do not widely distribute throughout the body with the same efficiency, thus
developing improved targeted drug delivery strategies is critical to realizing the promise of
oligonucleotide therapies.
Nevertheless, interest in RNA targeting drugs has grown in recent years as advances in our
understanding of RNA regulation and disease has improved. Early oligonucleotide-based
therapies were developed for pharmacologically convenient tissues in the human body, beginning
with the eye. Approved by the FDA over 20 years ago as a therapy for cytomegalovirus retinitis,
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the first antisense oligonucleotide to find use in humans, Fomivirsen, acted through blocking
translation of viral mRNAs and was delivered by intravitreal injection [187]. As advances in
oligonucleotide chemistry conferred greater resistance to degradation and improved
biodistribution, other routes of administration and mechanisms of action became feasible [186].
Subsequent RNA-based therapies have focused on modulating alternative splicing, or inducing
RNA degradation relying on intravenous administration for muscle targeting or intrathecal delivery
for targeting neurons [185]. Despite these advances, oligonucleotide delivery remains much less
efficient than for small molecules, and devising improved methods for targeted delivery remains a
key bottleneck to the translational application of oligonucleotides for therapy [188].
Informed by our growing appreciation for the diversity of RNA regulatory mechanisms, there is
now increasing interest in new strategies for changing protein expression at the RNA level.
Indeed, approaches for targeting G-quadruplex elements and uORFs to modulate protein
expression have been proposed previously in the literature [189–191], and several preclinical
studies have been published with promising results across a number of human disease
contexts[192–196]. As catalogues of RNA regulatory elements encoded in the transcriptome
expand, so too will the possibilities of therapeutic manipulation.
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APPENDIX A: Methods for Integrative analysis reveals RNA G-quadruplexes in
UTRs are selectively constrained and enriched for functional associations
Identification of UTR G-quadruplex Sequences
Annotated UTR sequences and genomic coordinates were downloaded using biomaRt[189,190]
for Ensembl Transcript Database version 75 for all protein-coding transcripts. Putative Gquadruplex forming sequences (pG4) were identified using this set of annotated UTRs by
performing a pattern-matching text search to identify regions of UTRs matching the canonical Gquadruplex pattern as a regular expression: (G:3+)-{N:1-7}(3)-(G:3+). Genomic coordinates for
pG4 sequences within UTRs were obtained using a custom python script, and cross-referenced
with annotated protein-coding regions of the genome from the Ensembl Transcript Database to
remove overlaps between annotated UTRs and coding sequences using human genome hg19
coordinates. The identified set of 5’ and 3’ pG4 sequences, and corresponding genomic
coordinates were used for all downstream analysis. This approach yielded a total of 5235 proteincoding genes harboring a UTR pG4 sequence, with 2967 genes having a 5’UTR pG4, and 2835
genes having a 3’UTR pG4. Of the 5235 genes with either a 5’ or 3’ UTR pG4, 567 have both.
A second set of pG4 sequences with evidence of secondary structure formation was defined by
overlapping pG4 motifs identified transcriptome-wide with published in vitro rG4-seq annotations
by using the K+PDS conditions [63]. Only the subset of rG4-seq G4s matching the canonical pG4
motif were used in this analysis. For the set of rG4 sequences, we find 243 protein-coding genes
encoding a 5’UTR rG4, and 803 genes encoding a 3’UTR rG4. Of these rG4 genes, 16 have 5’
and 3’ UTR pG4 encoding transcript isoforms.

Constraint Analysis
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Variants from gnomAD release 2.2.1 were obtained from (URL here:
https://gnomad.broadinstitute.org/downloads) and filtered to exclude those marked with
segmental duplication, low complexity regions (LCR), and decoy flags, in addition to those
variants whose True Positive probability as determined by a random forest model trained in
gnomAD did not exceed 40% [44]. As an additional requirement, only those variants where the
total observed allele number was at least 80% of the maximum number of sequenced alleles was
considered to control for differences in sequencing depth in the gnomAD WGS dataset. The
remaining set of high-confidence variants was overlapped with genomic coordinates for UTR
pG4, non-pG4, and CDS regions, using bedtools2 (version 2.27.1) intersect with the -u and -b
flags.
The transcript constraint-table from gnomAD release 2.2.1 (URL
https://gnomad.broadinstitute.org/downloads) was used to randomly select a matching set of
transcript-level constraint-matched non-pG4 UTR sequences based on the gnomAD observed /
expected metric for the 5’ UTR and 3’ UTR separately. Specifically, transcript constraint was
matched between pG4 and non-pG4 forming sequences using the observed versus expected
ratio of loss of function variants metric (LOEUF) provided for each transcript by gnomAD.
The fraction of variants per sequenced allele across UTR regions were computed as the fraction
of the observed allele count versus observed allele number. The distribution of frequencies for
variants mapping to each UTR region was extracted from the gnomAD summary variant call files
directly. P-values for difference between the expected number of variants per sequenced allele
across genomic regions were calculated using a two-sided Fisher exact test. Only variants that
did not overlap annotated coding regions of the transcriptome were compared to ensure that
UTRs overlapping coding regions of other transcript isoforms were excluded. All statistical tests
were conducted for 5’UTR and 3’UTR features separately.

96

For positional constraint analysis, we applied the mutability-adjusted proportion of singletons
(MAPS) metric [37] for each nucleotide position across all trinucleotide G-tracts with G4-forming
capacity, as defined by our bioinformatic analysis. We developed a MAPS model using custom
code based on a previously published MAPS model (https://github.com/pjshort/dddMAPS) with
the addition of adjusting for methylation levels at variant positions. We divide variants by median
estimated methylation levels across 37 tissues at CpG sites into None/Low (<0.2), Intermediate
(0.2-0.6), or High (0.6<) bins for which separate methylation-adjusted mutation rates were
available. Our model was trained by regressing the observed proportion of singleton synonymous
variants for each trinucleotide context within protein-coding regions of the genome on mutation
rates for each trinucleotide context (methylation-adjustment was performed only at CpG
dinucleotides) derived from intergenic noncoding regions of the genome [137]; [44]. All variants
used in this analysis, including synonymous variants used for training the model, were subject to
the same filtering requirements as used in the analysis of allele frequencies (random forest True
Positive probability exceeding 40%, and total observed allele number was at least 80% of the
maximum number of sequenced alleles). To control for ambiguity regarding which specific
guanines within each G-tract are involved in pG4 formation for G-tracts having more than 3
guanines, we considered only variants within trinucleotide G-tracts. MAPS values were also
determined for the set of variants with a VEP consequence of missense, or those variants
predicted to cause a loss of function (pLoF) in gnomAD to provide context for the different
degrees of purifying selection acting over a set of variants. pLoF variants were defined as those
annotated with Ensembl predictions for having a high impact and includes transcript_ablation,
splice_acceptor_variant, splice_donor_variant, stop_gained, frameshift_variant, stop_lost, and
start_lost terms. In our assessment of positional constraint within the meta-pG4 sequence
consisting of only trinucleotide G-tracts, we calculated MAPS for four categories of pG4 variants:
1) all genes, 2) genes with at least one transcript falling in the upper one-third of transcripts that
are most intolerant to loss of function mutations (as determined by the gnomAD o/e metric), 3)
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alternative pG4 genes, and 4) alternative pG4 disease-associated genes extracted from ClinVar
database (April, 2019 release). Permutation P-values were obtained by performing 10,000
bootstraps for each set of pG4 variants in gnomAD with replacement to produce a distribution of
MAPS score for each variant context; and then comparing these distributions to a matched set of
resampled MAPS scores using either all UTR variants, or position-matched non-pG4 GGG/CCC
trinucleotide variants to determine the proportion of bootstrapped samples whose MAPS score of
pG4 regions exceeded the matched non-pG4 variant set.
Posterior substitution probabilities for noncoding regions of the genome based on local
heptameric sequence contexts were obtained from a published model [75] based on the Phase 1
release of the 1000 Genomes Project. Cumulative substitution probabilities for each of the
possible mutations within a heptamer context (e.g. A→C, A→T, A→G) were calculated by
summing over all nucleotide substitution probabilities for a given heptamer context. To produce a
null distribution of observed / expected number of substitutions for non-pG4 regions of the UTR,
we randomly sampled 5000, 25 nucleotide UTR regions from constraint-matched transcripts,
10,000 times to generate a null distribution. Specifically, constraint-matched non-pG4 transcripts
were divided into heptamers using a sliding window across the entire region, and substitution
probabilities based on heptameric context alone was summed for each nucleotide position of
each region to estimate the expected substitution frequency across each region of interest. The
number of expected substitutions as derived from the heptamer substitution model for a given
region was compared to observed substitutions for the European subpopulation within the Phase
1 of the 1000 Genomes Release. We performed comparisons across UTR pG4 G-tracts, pG4
non-G-tract Gap sequences, and constraint-matched non-pG4 UTRs for all pG4s, and the subset
of rG4-seq supported pG4 motifs. Because the model does not adjust for methylation at CpG
dinucleotides, all CpG dinucleotide positions within UTRs were removed from consideration.
Statistical significance was determined by randomly sampling a set of genomic positions from
each region of interest with replacement, matching the original combined size of each region,
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over 10,000 iterations to produce a distribution of observed / expected ratios for each region of
interest. P-values for each region (pG4, rG4, gap sequences) were calculated as the proportion of
the observed / expected ratios obtained from the above bootstrapping procedure that were less
than a matched set of observed / expected ratios using all 5’ and 3’UTR genomic positions
obtained by the same procedure.

pG4 Isoform Expression Across Tissues in GTEx
The median expression of each annotated RNA transcript (as measured in units of TPMs) in each
tissue context was downloaded from GTEx v7. Median TPMs for each transcript were extracted
for all pG4- or non-pG4 containing transcript for each pG4 gene, the highest expressed pG4 or
non-pG4 isoform was selected, and a threshold of 1 TPM was used to determine expression
within a specific tissue context. pG4 transcripts were deemed constitutive if only one of the pG4,
or none of the non-pG4 transcripts exceeded this threshold, and labeled alternative if both the
pG4, and non-pG4 transcripts exceeded this threshold. Significance of the distribution of
alternative versus constitutive UTR pG4-encoding genes was assessed by randomly assigning
pG4 and non-pG4 transcripts each gene, maintaining the number of transcript isoforms encoded
by each gene constant with the condition that each gene should contain at least 1 pG4-encoding
transcript. The distribution of the ratio of alternative to constitutive pG4 genes from the randomly
distributed pG4 transcripts was then computed over 10,000 iterations to obtain a P-value for the
true ratio of alternative to constitutive UTR pG4 encoding genes.

cis-eQTL and protein-binding enrichment
Significant variant-gene pairs were obtained from GTEx release version 7 (URL:
https://gtexportal.org/home/datasets) constituting the set of nominally significant cis-eQTLs. Lead
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cis-eQTL variants for each gene were defined as the variant with the lowest P-value for each
gene, from the set of all significant variants in each tissue context separately. The set of lead and
nominally significant variants was overlapped with UTR pG4 and non-pG4 regions of the UTR,
and the number of significant cis-eQTL variants per region was compared to the number of nonsignificant tested SNPs occupying the same region to determine the proportion of cis-eQTLs
compared to non-cis-eQTL SNPs. UTRs with cis-eQTLs not associated with changing the
expression of the parent gene were excluded this analysis. Enrichment of cis-eQTLs was
computed using a two-sided Fisher Exact Test. The set of causal eQTL candidates were obtained
directly from the supplemental material of Brown et. al [80], and enrichment statistics were
computed using GTEx v6p tested SNPs instead of v7 to match the data used in that study.
The direction bias of nominally significant cis-eQTLs within UTR pG4 G-tracts versus non-G-tract
variants was computed by binarizing the normalized effect size pre-computed for each QTL by
GTEx, and comparing the proportions of QTLs in each feature with either a positive effect, or
negative effect on gene expression for each possible cis-eQTL annotation across all tissue
contexts combined. Statistical significance was determined by a two-sided Fisher Exact Test.
High-confidence protein-binding sites were obtained from ENCODE CLIP-seq summaries and
only peaks called with an Irreproducible Discovery Rate = 1000 were used for downstream
enrichment analyses as determined by ENCODE [82]. Overlapping binding sites for multiple
proteins were collapsed into a single protein-binding site, and the density of unique binding sites
overlapping UTR pG4 regions compared to non-pG4 regions of the UTR was compared by
dividing the number of CLIP-seq peaks overlapping each feature by the total number of
nucleotides in each region. Significance was assessed using a chi-square test with 2 degrees of
freedom.
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Proteins whose binding sites are enriched for pG4 overlaps were computed using a
hypergeometric test, by comparing the proportion of set of pG4 containing versus non-pG4
binding sites for a given RBP compared against the background proportion of of all UTR CLIPseq peaks containing a pG4 sequence. The significance of pairwise overlaps between proteingene targets was also computed using a hypergeometric test to assess the degree that one
protein’s pG4 binding genes were also targets for another protein.

Gene Expression with RBP Knockdown in ENCODE
Processed differential gene expression tables for K562 and HepG2 were obtained directly from
ENCODE (https://www.encodeproject.org/) for each of the pG4-enriched binding proteins and
their respective knockdown experiments. For each experiment, a gene was considered
differentially expressed at an FDR threshold of < 0.05. Genes from ENCODE differential
expression tables were annotated as either a pG4 gene or non-pG4 gene on the basis of whether
they encoded for a transcript isoform possessing a UTR pG4 sequence in either the 5’UTR or
3’UTR. The odds ratio for being significantly differentially expressed was calculated by comparing
the ratio of pG4 to non-pG4 genes reaching statistical significance for differential expression
between shRNA knockdown of the RBP, and the control for each protein separately. Statistical
significance was determined by Fisher’s Exact Test and FDR was controlled at 0.001 by applying
the Benjimini-Hochberg procedure to the resultant P-values for each cell line. The direction of
effect on pG4 gene expression for protein knockdown to cause an increase or decrease in pG4
gene expression was determined by taking the median value for log2-fold change in expression
for all pG4-containing genes measured in a given experiment.

Variants in ClinVar and the NIH-GWAS Catalogue
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The April 2019 release of ClinVar was obtained from ftp://ftp.ncbi.nlm.nih.gov/pub/clinvar/. Using
these variant annotations, we identified a subset of disease associated genes as any gene with at
least one variant having a Pathogenic or Likely Pathogenic annotation. These genes were used
to subset the ClinVar database and all variants spanning 40 nucleotides or less were overlapped
with UTR regions to assess for enrichment in pG4 sequences. Insertions or deletions spanning
greater than 40 nucleotides were not considered in this analysis, nor were any variants with an
annotation of Benign or likely benign in Clinvar. The number of variants across each region was
then divided by the total number of bases in each respective region to estimate of the density of
variation in a given region. The odds ratios for the number of single nucleotide variants compared
to the number of bases in a given region were then compared using a two-sided Fisher Exact
Test.
For identification of GWAS-implicated SNPs affecting annotated UTR pG4 sequences, publicly
available phenotype-associated SNPs from were obtained from the NIH-EBI GWAS Catalogue.
Genomic coordinates for GWAS SNPs were converted from hg38 to hg19 coordinates using the
NCBI Genome Remapping Service (https://www.ncbi.nlm.nih.gov/genome/tools/remap). This set
of lead GWAS SNPs was used to identify nearby linked SNPs in high LD using the Linkage
Disequilibrium Calculator tool from the Ensembl GRCh37 website using a 50KB window
surrounding each lead GWAS SNP and selecting the set of SNPs with r 2 > 0.85 using the GBR
population of the 1000 Genomes Project.

Allele-specific expression for GWAS-variants
RNA-seq libraries were trimmed using TrimGalore [191]. Reads were aligned to the GRCh37
human genome using STAR (version 2.7.0c) with the WASP-filtering option, and matched wholegenome sequencing variant files obtained from GTEx for Skeletal Muscle, Thyroid, Fibroblast,
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Esophagus, and Tibial Nerve tissue samples. Reads that did not pass WASP-filtering were
removed from the resulting aligned bam files. PCR duplicates were removed using the python
script remove_duplicates.py included in the WASP version 0.3.3 pipeline
(https://github.com/bmvdgeijn/WASP). Read counts matching the reference and alternate alleles
in the resultant WASP-filtered bam files were compiled using bcftools mpileup across UTR pG4
variants. A beta-binomial model was fitted using the R VGAM package [192] for each variant
across all heterozygous samples identified using matched whole-genome sequencing from GTEx
to estimate the ratio of reference reads to alternate reads. Estimates of statistical significance
were obtained by using a likelihood ratio test comparing the log-likelihood of the observed count
distribution for each variant using the beta-binomial estimate for ρ versus the null hypothesis of
no bias (ρ = 0.5).

Code Availability
All analysis scripts used to generate the primary results and figures reported in this study are
publicly available from: https://bitbucket.org/biociphers/g4-paper-2019/src/master/.

Data Availability
Pre-processed data, and instructions for how to access public data resources used in this study
that can be used to regenerate the primary figures of this analysis have been uploaded to
https://bitbucket.org/biociphers/g4-paper-2019/src/master/. A subset of the processed publicly
available data underlying Figs 3, 4, and 5 are included in this repository, with associated
instructions on how to access other data as required to regenerate these figures where
necessary. This repository also contains a link to a Source Data file which contains raw data
underlying Figs 1b-d, 3a, b, 4a-d, 5a, c, d, and Supplementary Figs 5 and 7. Genetic variation
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data from The Genome Aggregation Database version 2 release are available from:
https://gnomad.broadinstitute.org/downloads. Gene expression and cis-eQTL mapping data from
the Genotype Tissue Expression Project version 7 release are available from the GTEx Portal
website: https://gtexportal.org/home/. RNA-seq data used for allelic imbalance analysis are
available from dbGaP (phs000424.v7.p2 [https://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study_id=phs000424.v7.p2]). RNA-protein binding interaction data can be retrieved
from the ENCODE Consortium: https://www.encodeproject.org/. GWAS-associated variation data
can be accessed from the NIH-EBI GWAS Catalog: https://www.ebi.ac.uk/gwas/. A copy of the
filtered ClinVar database used to generate Fig. 5a is included in the code repository from April
2019. The most updated version of disease-associated genetic variant annotations are also
available from ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/.

Statistics
Data were analyzed and statistics performed using R (version 3.5.0) and Python (version 3.7 and
3.6.1).

104

APPENDIX B: Methods for Disrupting upstream translation in mRNAs is
associated with loss-of-function in human disease
Annotation of translated non-canonical open reading frames
Non-canonical ORF (ncORF) annotations encompassing 5’UTR ORFs (uORFs), 3’UTR ORFs
(dORFs), long-noncoding RNA ORFs (lncRNA) and pseudogene ORFs were retrieved from
Supplementary File 1 from Ji et al. [121]. These ncORFs were mapped by ribosome-profiling in
human BJ fibroblasts and MCF10A breast epithelial cells using the RibORF algorithm. Using the
final set of genomic coordinates for ncORFs identified in this study, we converted these
coordinates to match hg38 annotations using the UCSC LiftOver executable
(https://genome.ucsc.edu/cgi-bin/hgLiftOver). Out of 10,007 distinct non-canonical uORFs
mapped in the original study, 27 whose length changed after conversion (N = 5 uORFs, 4 dORFs,
16 lncRNA ORFs, 2 pseudogenes) were excluded from subsequent analyses. Each Refseq
mRNA ID for each ORF-associated RNA transcript was annotated to its associated Ensembl
transcript ID using the BioMart database v86 annotations. The first three nucleotides of each ORF
were used as start codons for downstream analyses. The final three nucleotides of each ORF
were used as stop codons for downstream analyses. 5’ and 3’ UTR definitions used in this study
are derived from the Ensembl v86 annotations.

Quality filtering and annotation of variants from gnomAD version 3
Variants from gnomAD 3 release were downloaded from the gnomAD browser website
(https://gnomad.broadinstitute.org/downloads). A set of high-confidence variants were obtained
by removing those failing the Filter column (Filter != PASS) from the gnomAD version 3 vcf files
using bcftools (version 1.9), and those falling in low complexity regions (lcr != 1). This set of
variants was used for all downstream analyses. We additionally removed variants where the total
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observed allele number was at less than 80% of the maximum number of sequenced alleles to
control for differences in sequencing depth in the gnomAD WGS dataset. The remaining set of
high-confidence variants was overlapped with genomic coordinates for annotated ncORFs, 5’UTR
sequences, and annotated protein-coding sequences using bedtools (version 2.27.1) intersect
with the -u and -b flags. The predicted consequence of each variant was obtained using the
Ensembl Variant Effect Predictor (VEP, version 98.2) based on hg38 gene models obtained from
Ensembl. VEP consequences were further filtered to only include the predicted consequence for
the canonical Ensembl transcript as determined in [136].

Positional constraint analysis using variants from gnomAD
For the positional constraint analysis we applied the MAPS metric to each variant set. We
developed a MAPS model following previous methods [136]. The set of synonymous proteincoding variants are used as a baseline measurement for neutral selection, and the proportion of
singletons in a variant class are adjusted for differences in mutation rates due to local sequence
context [37,136]. We trained our model by regressing the observed proportion of singletonsynonymous variants for each trinucleotide context within protein-coding regions of the genome
using previously published context-dependent mutation rates derived from intergenic noncoding
regions of the genome [136]. Since negative selection prevents deleterious mutations from
becoming common in human populations, more deleterious mutations - including those disrupting
essential splice sites or introducing premature termination codons - are also more enriched for
singletons compared to neutral variants.
MAPS scores for a given set of variants are calculated as described previously [37,135,136].
Briefly, for a given set of variants, we use the MAPS model to determine the expected number of
singletons that should be observed, based on the transformed mutation rates which account for
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trinucleotide context and methylation levels. To calculate the MAPS score, we take the observed
number of singletons for this set of variants, and subtract the expected number of singletons
calculated using the MAPS model. We then divide this value by the number of variants total to
obtain the proportion of singleton variants adjusted for mutation context.
To estimate of MAPS scores for missense-causing mutations in canonical protein-coding
sequences within the genome, we selected the subset of SNVs in gnomAD with an annotated
VEP consequence of missense, and removed SNVs from this set of variants if they had additional
VEP annotations that could be considered predicted loss-of-function (pLoF). The set of variants
used to calculate MAPS scores for pLoF variants relied on aggregating variants with a VEP
annotation of transcript_ablation, splice_acceptor_variant, splice_donor_variant, stop_gained,
frameshift_variant, stop_lost, and start_lost terms. The set of synonymous variants used to train
the MAPS model was filtered to remove variants with any of the previous predicted high impact
annotations, and those with a possible missense consequence.
We computed MAPS scores for each set of variants based on uORF annotations, or 5’UTR
annotations from Gencode (GRCh38.p13;
https://www.gencodegenes.org/human/release_32.html). Using the set of filtered variants we
matched them to uORF positions annotated by their relative position within the uORF reading
frame, strand, and codon. We determined how the mutation affected the codon within the
translated uORF sequence, and annotated each variant with its consequence on the encoded
amino acid. We used these annotations to select variants that could introduce new stop codons
(UTC-introducing variants) and those that strengthened existing stop codons within uORFs. For
UAA-introducing variants we selected any variant that produced an in-frame UAA stop codon. For
each set of stop-introducing or stop-strengthening variants, we selected a set of uORF variants
matching the underlying trinucleotide context of each experimental set of variants. MAPS scores
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for these variant sets were computed and confidence intervals were determined by resampling
from each variant set with replacement over 10,000 iterations.
For codon optimality analysis, we used the set of codon stability coefficients (CSC) scores
derived from SLAM-seq in 562 cells obtained from https://doi.org/10.7554/eLife.45396.006 [153].
Optimality decreasing variants were defined as any variant which decreased the CSC score for
the encoded codon, and optimality increasing variants were defined as any variant which
increased the CSC score for the encoded codon.
Confidence intervals for MAPS scores were calculated using bootstrapping as described [135].
For each set of n variants used to compute a MAPS score, we select n variants randomly with
replacement and recalculate MAPS scores. This is repeated over 10,000 permutations and the
5th and 95th percentiles of the MAPS scores distribution are used as confidence intervals. Pvalues for differences in MAPS scores were determined by calculating the proportion of
bootstrapped MAPS scores from an experimental group of variants that were larger than those
from the control group [135].

Determining the distribution of stop codons used by upstream open reading frames
Stop codons from each uORF were extracted based on genomic coordinates and the uORF
reading frame. Confidence intervals were determined by sampling with replacement from the set
of uORF stop codons over 10,000 iterations. For 5’UTR sequences, all stop-codon matching
trinucleotides (UGA, UAG, UAA) were extracted from annotated canonical 5’UTR sequences of
protein-coding genes in the BioMart Ensembl database (version 86). The set of canonical
transcripts annotated in the gnomAD flagship release paper were used to define 5’UTR
sequences for this analysis [136]. For each iteration, one stop codon was randomly selected from
each 5’UTR and the proportion of UGA, UAG, and UAA trinucleotides selected from all 5’UTR
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sequences were calculated. This procedure was repeated 10,000 times to form a distribution of
TGA, TAG, and UAA trinucleotides in all 5’UTR sequences. This procedure was also repeated for
uORF-matched UTR sequence segments that did not overlap known translated uORFs. P-values
for the depletion of UAA stop codons used in translated uORFs were calculated by determining
the number of bootstrap iterations where the frequency of UAA codons from uORFs was higher
compared to non-uORF sequences. P-values for enrichment of UGA and UAG sequences were
calculated by determining the fraction of sampled iterations where fewer UGA and UAG
sequences were selected from uORF stop codons compared to all 5’UTRs and uORF-matched
5’UTR sequences respectively.

Assessing variant conservation using genome-wide phyloP scores
PhyloP scores for each base were downloaded from the UCSC genome browser
(http://hgdownload.cse.ucsc.edu/goldenpath/hg38/phyloP100way/). 1-indexed bigwig files were
converted to bed file format using the wig2bed tool from bedops (version 2.4.36;
https://bedops.readthedocs.io/en/latest/index.html). These base-level annotations were matched
to each uORF base and used to determine the proportion of bases that were significantly
conserved (proportion of bases with phyloP score > 2). Possible inframe stop-codon creating
positions were identified based on mapped reading frames for each uORF. These sites were
extracted and further categorized by whether or not a mutation could create a UGA, UAG, or UAA
stop codon. Some positions could be mutated to either a UGA, UAG or UAA codon and these
were considered separately from potential UGA, UAG or UAA-creating positions. We have
included all potential stop-introducing positions in Suppl. File 1. As a control we used phyloP
scores for genomic positions with the potential to create non-uORF UGA, UAG, or UAA
trinucleotides by mutation, but matched by distance to CDS in 10-base pair windows.
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Start-disrupting genomic positions were annotated as those mutating the second or third position
in the first codon of each translated uORF. Conservation based on phyloP scores were assessed
for start-disrupting positions similar to potential stop-introducing positions. As a control we
compared phyloP scores for uORF start-disrupting positions to out-of-frame start-disrupting
positions within annotated uORFs, and a set of NTG start-disrupting variants that were not part of
translated uORFs but matched by distance to the CDS as determined by 10-bp windows.
P-values were determined by sampling with replacement from each set of variants 10,000 times
and re-calculating the proportion of significantly conserved bases (phyloP score > 2). The
distribution of the fraction of conserved base positions were then compared against different sets
of variants, and the P-value was defined as the fraction of samples where one group was higher
than the other.

Setting and study participants
All individuals who were recruited for the Penn Medicine Biobank (PMBB) are patients of clinical
practice sites of the University of Pennsylvania Health System. Appropriate consent was obtained
from each participant regarding storage of biological specimens, genetic sequencing, access to
all available electronic health record (EHR) data, and permission to recontact for future studies.
The study was approved by the Institutional Review Board of the University of Pennsylvania and
complied with the principles set out in the Declaration of Helsinki. Replication analyses were
conducted using the whole exome sequencing (WES) dataset from the UK Biobank (UKB).
Genetic sequencing
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This PMBB study dataset included a subset of 11,451 individuals in the PMBB who have
undergone WES. For each individual, we extracted DNA from stored buffy coats and then
obtained exome sequences generated by the Regeneron Genetics Center (Tarrytown, NY).
These sequences were mapped to GRCh37 as previously described [155]. Furthermore, for
subsequent phenotypic analyses, we removed samples with low exome sequencing coverage
(i.e. less than 75% of targeted bases achieving 20x coverage), high missingness (i.e. greater than
5% of targeted bases), high heterozygosity, dissimilar reported and genetically determined sex,
genetic evidence of sample duplication, and cryptic relatedness (i.e. closer than 3rd degree
relatives), leading to a total of 10,900 individuals.
For replication studies in UKB, we interrogated the 32,268 individuals of European ancestry
(based on UKB’s reported genetic ancestry grouping) with ICD-10 diagnosis codes available
among the 49,960 individuals who had WES data as generated by the Functional Equivalence
(FE) pipeline. We focused our replication efforts on 32,268 individuals after removing samples
with poor genotype quality, individuals closer than 3 rd degree relatives, and those with dissimilar
reported and genetically determined sex. The PLINK files for exome sequencing provided by UKB
were based on mappings to GRCh38. Access to the UK Biobank for this project was from
Application 32133.

Variant annotation and selection for association testing
For both PMBB and UKB, genetic variants were annotated using ANNOVAR [193] as 5’
untranslated region (5’ UTR), predicted loss-of-function (pLOF), or missense variants according
to the NCBI Reference Sequence (RefSeq) database [193,194]. Rare (MAF ≤ 0.1%) pLOF
variants were defined as frameshift insertions/deletions, gain/loss of stop codon, or disruption of
canonical splice site dinucleotides. Predicted deleterious rare (MAF ≤ 0.1%) missense variants
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were defined as those with Rare Exonic Variant Ensemble Learner (REVEL) [195] scores ≥ 0.5.
pLOF and REVEL-informed missense variants were selected for gene burden testing to validate
the robustness of significant uORF variants’ corresponding gene-disease associations.

Clinical data collection
International Classification of Diseases Ninth Revision (ICD-9) and Tenth Revision (ICD-10)
disease diagnosis codes and procedural billing codes, medications, and clinical imaging and
laboratory measurements were extracted from the patients’ EHR for PMBB. ICD-10 encounter
diagnoses were mapped to ICD-9 via the Center for Medicare and Medicaid Services 2017
General Equivalency Mappings (https://www.cms.gov/Medicare/Coding/ICD10/2017-ICD-10-CMand-GEMs.html) and manual curation. Phenotypes for each individual were then determined by
mapping ICD-9 codes to distinct disease entities (i.e. Phecodes) via Phecode Map 1.2 using the
R package “PheWAS” [156,196]. Patients were determined to have a certain disease phenotype
if they had the corresponding ICD diagnosis on two or more dates, while phenotypic controls
consisted of individuals who never had the ICD code. Individuals with an ICD diagnosis on only
one date as well as individuals under control exclusion criteria based on PheWAS phenotype
mapping protocols were not considered in statistical analyses.
For UKB, we used the provided ICD-10 disease diagnosis codes for replication studies, and
individuals were determined to have a certain disease phenotype if they had one or more
encounters for the corresponding ICD diagnosis given the lack of individuals with more than two
encounters per diagnosis, while phenotypic controls consisted of individuals who never had the
ICD code. Individuals under control exclusion criteria based on PheWAS phenotype mapping
protocols were not considered in statistical analyses.
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Association studies
A phenome-wide association study (PheWAS) approach was used to determine the phenotypes
associated with 5’ UTR variants predicted to create new UAA UTCs, or strengthen existing uORF
stop sites and carried by individuals in PMBB for the discovery experiment [156]. Each disease
phenotype was tested for association with each uORF variant using a logistic regression model
adjusted for age, age2, sex, and the first ten principal components (PCs) of genetic ancestry. We
used an additive genetic model to collapse variants per gene via an extension of the fixed
threshold approach [197]. Given the high percentage of individuals of African ancestry present in
the discovery PMBB cohort, association analyses were performed separately in European
(N=8198) and African (N=2172) genetic ancestries and combined with inverse variance weighted
meta-analysis. Only 5’ UTR variants with at least five total alternate alleles in PMBB were
selected for univariate PheWAS analyses in the discovery phase while variants with greater than
half of the genotypes annotated as missing due to low quality were excluded. This resulted in a
final set of N=10 variants. Our association analyses considered only disease phenotypes with at
least 20 cases, leading to the interrogation of 800 total Phecodes. All association analyses were
completed using R version 3.3.1 (Vienna, Austria).
We evaluated the robustness of significant uORF-phenotype associations in the same PMBB
discovery cohort by aggregating pLOF and predicted deleterious missense variants in each
uORF’s corresponding gene into a ‘gene burden’ for hypothesis-driven association with the
significant phenotype from discovery. Only gene burdens with at least five total alternate alleles in
PMBB were selected for replication studies. All gene burden association studies in PMBB were
based on a logistic regression model adjusted for age, age2, sex, and the first 10 PCs of genetic
ancestry.
Additionally, we replicated our findings in UKB for significant uORF associations in the PMBB
discovery using 1) hypothesis-driven univariate association studies for the same uORF variants
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and 2) hypothesis-driven gene burden collapsing pLOF and predicted missense variants for the
corresponding genes. Only uORF variants and gene burdens with at least five total alternate
alleles in PMBB were selected for replication studies. Association statistics were calculated
similarly to PMBB, such that each disease phenotype was tested for association with each gene
burden or single variant using a logistic regression model adjusted for age, age 2, sex, and the first
10 PCs of genetic ancestry. Replication significance was defined using a P-value threshold of
0.05. All association analyses for PMBB and UK Biobank completed using R version 3.6.1.

Construction of expression vectors
The test plasmids used a modified pGL4.12[luc2CP] (Promega) vector backbone where the
control of expression of the Firefly ORF was modified by the addition of an upstream CMV
promoter. The modified pGL4.12 vector was linearized using Bgl-II and MreI restriction sites.
Hybrid 5’UTR fragments containing the entire 5’UTR sequence and the first 91 nucleotides of the
Luc2 Firefly ORF were produced by gBlock synthesis and received from Integrated DNA
Technologies using sequences in Suppl. Table 3. Test plasmids were constructed by sub-cloning
these hybrid 5’UTR sequences for PMVK, VPS53, and BCL2L13 into the modified pGL4.12
vector to preserve the uORF-CDS relationship for each construct. Correct fragment insertion was
verified for each engineered construct by sanger sequencing. For PMVK and BCL2L13, the entire
annotated 5’UTR sequence was used. For VPS53, because of a G-rich sequence in the 5’UTR
upstream of the uORF complicated synthesis of the gene’s entire 5’UTR fragment, we removed
the first 75 nucleotides of the annotated 5’UTR sequence. Construct assembly was accomplished
using the NEB Hi-Fi assembly protocol following manufacturer’s instructions.

Cell culture and transfections
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HEK293T cells were used for conditional expression of reporter genes. For transient
transfections, HEK293T cells were split 1 day before transfection and seeded in 24-well plates at
a density of 100,000 cells per well. 2 ug of the test Firefly reporter plasmid was transfected into
each well using Lipofectamine 3000 following the manufacturer’s protocol using 1.5 uL of
transfection reagent and 0.5 uL of the P3000 reagent for each well. As a control for transfection
efficiency, 0.02 ug of the pRL-CMV Renilla Luciferase plasmid (Promega Accession No.
AF025843) was co-transfected with firefly luciferase plasmids. Biological replicates were obtained
by transfecting cells from separate passages on separate days using newly prepared reagents.
All transfections were repeated using the HeLa cell line. Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum and antibiotics was used for all cell
culture.

Luminometry assays
Luminescence was measured using the Promega Dual-Luciferase Reporter Assay System
(E1910) following the manufacturer’s protocol. Cells were lysed by adding 100 uL of lysis buffer
10 uL of each lysate was transferred to a black opaque 96-well plate. The ratio of Firefly to
Renilla luminescence with a microplate reader by automatic injection of the Luciferase Assay
Reagent II and Stop & Glo reagents. Biological replicates were obtained by transfecting cells from
separate passages on separate days using newly prepared reagents. Luminescence
measurements were compared within each set of transfections and statistical significance was
determined using a one-sided T-test comparing the firefly to Renilla expression ratio of each test
construct normalized to the wild-type construct.
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Code Availability
All scripts used in this analysis except for those generating PheWAS results and plots can be
accessed from https://www.bitbucket.org/biociphers/uorf-paper-2020/src

Data Availability

Data

Description

URL

gnomAD

The set of variants obtained from

https://gnomad.broadinstitute.org/downloads

variants

71,702 whole genome

(version 3)

sequences used for MAPS
analysis

Mapped

5’UTR (uORF), 3’UTR (dORF),

Non-

long-noncoding RNA, and

canonical

pseudogene ORFs mapped by

ORFs

the RibORF algorithm from

https://doi.org/10.7554/eLife.08890.023

ribosome-profiling data

CSC scores

Codon-stability coefficient scores
as determined by several
techniques

Software Availability
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https://doi.org/10.7554/eLife.45396.006

Software

Version

URL

Python

3.7.3

https://www.python.org/downloads/release/python-373/

R

3.6.1

https://cran.r-project.org/bin/windows/base/old/3.6.1/

bedtools

2.27.1

https://github.com/arq5x/bedtools2/releases

bcftools

1.9

http://samtools.github.io/bcftools/bcftools.html

Variant Effect Predictor

98.2

https://useast.ensembl.org/info/docs/tools/vep/index.html

(Ensembl)
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